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SUMMARY 
 
 The genome has been called the blueprint of life for it encodes a complete set of genetic 
instructions that specify the precise design and timing of functional molecules (such as RNAs 
and proteins) responsible for carrying out all cellular processes. In recent years, the human 
genome, comprised of approximately 3 billion nucleotide base pairs, has been decoded and 
determined to encode approximately 30,000 genes. This detailed genetic information has enabled 
the creation of advanced genomic technologies such as DNA microarrays that interrogate the 
structural and transcriptional dynamics of the genome on a comprehensive scale. However, the 
computational analysis of the output of genome-scale investigations has not been readily 
intuitive or subject to standardization. In this work, we have focused on the applications of 
genomic technologies towards the elucidation of cancer-related biomechanisms. From the 
development and coupling of analytical methodology and experimental design, to the prediction 
of genomic alterations from transcriptional measurements, this thesis describes a body of work 
aimed at extracting new fundamental insights into the pathobiology of cancer. Our genome-
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Chapter 1: Understanding Cancer from a Genomic Perspective 
 
1.0 Basis of cancer 
Cancer is a disease of the genome and the genesis and malignant progression of cancer is 
initiated by genetic insults to the DNA such as sequence mutations, structural chromosomal 
alterations and epigenetic modifications. In early tumorigenesis, DNA damage arising from the 
harmful effects of genotoxic agents such as ionizing radiation, intercalating agents and free 
radical oxidants, can negatively affect the coding and/or regulatory regions of certain genes, 
giving rise to mutant or dysregulated proteins with a gain of ―oncogenic‖ function (i.e., 
oncogenes) or with loss of tumor inhibitory activity (i.e., tumor suppressor genes). Alterations in 
these key genes spark a process of tumor progression marked by cumulative mutational events 
that invoke the inappropriate activation (or silencing) of a number of growth-regulating signaling 
pathways. Ultimately, these alterations converge on the selection of cells with certain malignant 
attributes such as the ability to replicate limitlessly, an affinity towards positive growth signals, 
disregard for growth suppressive signals, evasion of apoptosis, sustained angiogenesis and an 
ability to invade surrounding tissues and metastasize to distant organ sites [1].  
 
At the protein level, oncogenes and tumor suppressors act in a variety of cellular contexts 
and subcompartments to modulate growth regulatory mechanisms in cancer. The epidermal 
growth factor receptors, EGFR/erbB and HER2/neu (ERBB2), localized at the plasma 
membrane, are classic examples of cell surface receptors whose activation by ligands or genomic 
amplification and subsequent over expression results in proliferative, migratory and survival 
advantages that lead to tumor metastasis [2-4].  
  2 
The alteration of cytoplasmic components that receive and transduce signals originating 
from growth factor receptors can also contribute to cancer formation and progression. In the 
SOS-Ras-Raf-MAPK cascade, for example, mutations in the Ras oncogene, a GTPase whose 
physiologic role is to transduce extracellular signals in the MAPK (and PI3K) signaling 
pathways, can cause the constitutive activation of Ras resulting in the sustained transmission of a 
growth stimulatory signal that drives cellular proliferation. This cascade is connected to several 
downstream effector pathways and hence plays a central role in effecting tumorigenesis [5]. 
Activating Ras mutations are found in about 50% of colon carcinomas, 30-50% of lung 
adenocarcinomas, and more generally, in ~25% of all human cancers [6].  
 
 Alterations of growth negating signals that instruct cells to stop proliferating also occur, 
and these alterations affect tumor suppressor genes whose impact is often at the level of gene 
expression control. The Retinoblastoma gene (RB), discovered as the primary cause of the rare 
childhood eye tumor, retinoblastoma, is a central component in a pathway through which most 
anti-growth signals are transduced. The Rb pathway modulates the E2F transcription factors that 
in turn induce the expression of major cell cycle genes. Hyperphosphorylation of the Rb protein 
inhibits its sequestering activity over the E2Fs, thereby allowing E2F activity to drive 
uncontrolled cell proliferation [7]. The pathway can also be disrupted by a defective 
transforming growth factor beta (TGFβ) which transmits anti-proliferative signals through Rb. 
Malfunctions in other downstream elements can also converge on the RB pathway, further 
suppressing its growth inhibitory signals [8]. 
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 The discovery of the genes and pathways responsible for aberrant growth signals leading 
to cancer formation and progression is not only important academically, for a better 
understanding of cancer biology, but also is vital to the clinical goals of improved disease 
subtyping, patient prognosis and targeted therapeutics [9]. Clues to where these genes lie have 
historically been gathered through observation of the gross alterations in the cancer genome[10-
12]). These alterations take several forms, and are frequently described as amplifications (copy 
number gains), deletions (copy number losses), and balanced rearrangements (such as 
translocations, inversions and transpositions that involve the exchange of chromosomal material 
between two chromosomes or intrachromosomal regions) [13].   
 
Recurrent chromosomal aberrations have been reported in virtually all cancer types, often 
with clinical correlations. For example, in colorectal cancer it has been shown that patients with 
losses in chromosomal arms 1p, 4q, 8p, 14q, or 18q, or amplification of chromosomal arm 20q 
have poorer survival outcomes than those lacking these aberrations [14]. It has been estimated 
that more than 100 cancer-related genes have been identified through the discovery of nearly 600 
recurrent balanced chromosomal alterations. Balanced chromosome rearrangements either 
deregulate genes at their breakpoints or result in a fusion gene by a process of recombination. In 
many instances, these breakpoints harbor either an oncogene that gets activated, or a TS gene 
that gets inactivated, as a consequence of the rearrangement. For example, in Burkitt‘s 
lymphoma three translocations, t(8;14), t(8;22), and t(2;8), juxtapose the MYC gene at 8q24 to 
the constitutively active immunoglobulin genes (i.e., IGH at 14q32, IGL at 22q11 and IGK at 
2p12) resulting in Myc activation [15]. 
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Epigenetic modifications, such as the hypermethylation-mediated transcriptional 
silencing of tumor suppressor genes, is another common etiology of cancer [16, 17]. Recent 
studies have shown the involvement of hypermethylation in major pathways leading to cancer 
such as DNA repair (BRCA1, MGMT), cell cycle regulation (p14, p15, p16), apoptosis (DAPK, 
APAF-1), carcinogen metabolism (GSTP1), hormonal response (RARβ2) and cell adherence 
(CDH1, CDH3) [18-20]. Thus, cancer is a complex and heterogeneous disease, driven by a 
multitude of inappropriate signals with genomic alterations at their origin [21]. 
 
1.1  Historical views of the cancer genome 
As early as 1890, before the concept of the gene, clues to the connection between the genome 
(chromosomes) and cancer were observed when Hansemann postulated that asymmetric mitoses 
observed in some tumor cells were at the root of cancer formation [22]. In 1928, with the 
rediscovery of Mendel‘s work, genetic mutations were proposed as the origin of cancer, as an 
alternative to the infection theory of cancer [Bauer]. However, it would not be until 1969 that a 
technique would be developed to allow the recognition and tracing of individual chromosomes. 
Called chromosome banding, this approach was a major breakthrough in the field of cancer 
genomics as it enabled the study of chromosomal copy number and rearrangements. In this 
technique, chromosomes were chemically labeled with Giemsa stain (specific for DNA 
phosphate bonds) following a trypsin digestion resulting in a series of dark and light bands 
representing the AT-rich heterochromatic regions and the GC-rich euchromatic regions, 
respectively. These bands enabled researchers to visualize and thus order the chromosomes into 
pairs - a procedure termed ―karyotyping‖. The utility of this technique was definitively 
demonstrated when it was successfully used to discover the Philadelphia chromosome - a 
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reciprocal translocation designated as t(9;22)(q34;q11) that is the hallmark of chronic 
myelogenous leukemia [23]. Other cytogenetic tools followed, including fluorescence in-situ 
hybridization (FISH), Spectral Karyotyping (SKY) and comparative genomic hybridization 
(CGH), that helped cancer researchers locate regions of interest in the cancer genome. These 
techniques allow the reliable identification and characterization of complex chromosomal 
rearrangements and quantitative copy number changes.  
 
1.2  Modern methods of characterizing the cancer genome 
1.2.1  Fluorescence in-situ hybridization (FISH) 
Fluorescence in-situ hybridization (FISH) was the first of the so-called ―modern‖ 
cytogenetic techniques developed as an adjunct to the classical cytogenetic analysis [24]. In 
FISH, DNA probes of known origin are fluorescently labeled and hybridized to a metaphase 
chromosome spread or interphase nuclei. The probes anneal to the homologous sequences within 
the chromosome and are detected via fluorescence microscopy. Thus, FISH allows the 
quantitative determination of copy number status (i.e., amplification or deletion). For a specific 
chromosomal region, it provides visual information on which chromosome(s) received the 
amplified region (know as an amplicon). This technique is effectively used to study whole 
chromosomes or specific regions such as centromeres, telomeres, or specific genes, as well as 
juxtaposed chromosomal aberrations.  
 
1.2.2  Spectral karyotyping 
Spectral karyotyping or SKY is a multi-chromosomal painting assay that was developed 
to help visualize and distinguish chromosomes from one another. Like FISH, SKY is also a 
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fluorescence-based technique wherein fluorescently-labeled, chromosome-specific, composite 
probe pools are prepared and hybridized to metaphase or interphase cell spreads. Importantly, 
each probe pool incorporates a different fluorescent label, thus allowing the colorimetric 
discernment of individual chromosomes. This technique has become an indispensable tool for 
both basic research and diagnostic applications[25], as it provides a rapid means of identifying 
the numerical and structural chromosomal aberrations that characterize the cancer genome. 
 
1.2.3  Comparative genomic hybridization  
Comparative Genomic Hybridization (CGH) is a FISH-related technique developed to 
facilitate the ability to scan the entire cancer genome in an unbiased fashion for changes in DNA 
copy number[26]. In this technique, fluorescently labeled tumor DNA (e.g., fluorescein (FITC)) 
and normal DNA (e.g., rhodamine or Texas Red) are hybridized to normal human metaphase 
preparations. With the aid of epifluorescence microscopy and quantitative image analysis, 
regional differences in the fluorescence ratio indicating the gain or loss of tumor DNA can be 
detected and used for identifying abnormal regions in the genome. This method can only identify 
the copy number changes in the genome and hence is not useful for discovering balanced 
chromosomal changes like reciprocal translocations and inversions. While this technique has 
been effectively applied to cancer resulting in the discovery of genomic changes of clinical 
importance, the resolution of conventional CGH is poor, approximately 10Mbp, limiting its view 
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1.2.4  Microarray-based comparative genomic hybridization  
DNA microarrays are ordered collections of tens to hundreds of thousands of DNA 
(probe) sequences spotted onto a solid substrate such as chemically modified glass. Typically, 
these DNA probes are designed to be complementary to genes or genomic sequences, and upon 
hybridization with fluorescently labeled ―target‖ nucleic acid, will provide a semi-quantitative 
readout of specific nucleic acid levels. In the case of microarray comparative genomic 
hybridization (array CGH), the microarray probes can be designed to recognize individual genes 
(in the form of cDNA PCR products or synthetic oligonucleotides) [28-31] or long tracts of 
genomic sequence (such as bacterial artificial chromosome (BAC) clones) [32-34]. To this array, 
differentially fluorescently labeled genomic DNA from ―normal‖ and cancerous tissue can be 
hybridized, generating a fluorescence ―signal‖ ratio that reflects relative changes in genomic 
copy number between the cancer and normal tissue [35, 36] .  
 
Compared to traditional CGH which identifies genomic alterations on a ―macro‖ 
chromosomal scale, array CGH has the advantage of substantially higher resolution, as defined 
gene/genomic sequences are used to measure copy number status. Recently, state-of-the-art high-
density arrays comprised of >1x10
6
 tiled oligonucleotide probes have been reported to achieve 
genomic resolution of <20 kilo bases [37]. This high level of resolution allows the discovery of 
―micro‖ amplicons and deletions that may alter only a single gene [38].  
 
In addition to microarrays for studying the genome, microarrays for studying the 
transcriptome have also become a valuable molecular tool. The expression array measures gene 
activity or more specifically, mRNA levels on a genome-wide scale. Thus, the DNA probes of an 
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expression microarray are design to hybridized to the transcribed regions of genes, and 
fluorescently labeled cDNA (or cRNA) derived from cellular mRNA, is the target for an 
expression array hybridization [31]. 
 
1.3        Towards cancer gene discovery 
 Cytogenetic chromosomal mapping strategies such as FISH, SKY and CGH have 
traditionally been utilized as a starting point for uncovering oncogenes and tumor suppressor 
genes at genomic sites of recurrent amplification and deletion, as these regions are thought to 
harbor genes with causal roles in tumorigenesis. This approach has its limitations, however, as 
many candidate genes are often identified, and serial testing for the oncogenic properties of 
candidate genes is both costly and time consuming. Thus, new approaches are necessary for 
narrowing down the candidate gene lists, and recent studies suggest that the integration of 
multiple forms of information such as genomic, transcriptomic, biological, and even clinical data 
may provide a more successful strategy [39, 40]. 
 
1.4        Integrative genomic analysis 
Recent results from several laboratories suggest that combining microarray gene 
expression measurements with genome copy number data can enhance the cancer gene discovery 
process. While recurrent CNAs are believed to alter the expression levels of key cancer-
promoting genes, not all genes residing at a given CNA are necessarily dysregulated at the 
transcriptional level. By integrating CNA data from array CGH analysis with expression data 
from expression array analysis, one can study the correlations between copy number change and 
the transcriptional modulation of genes leading to the generation of candidate gene lists that can 
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be narrowed down by filtering for only those that show a statistically significant or ―best‖ 
correlation [41]. The intersection with clinical correlations can provide even further filtering for 
narrowing down candidates. Studies that rely on this principle of genomic and transcriptomic 
integration are generating new insights into mechanisms of human diseases including cancer 
[39].  
 
In a recent study by Chin et al, the combination of gene expression with copy number 
data was employed to improve the classification of patients according to clinical outcome [41]. 
The study demonstrated that the genes deregulated by the recurrent genome CNAs serve as 
efficient biomarkers to determine the treatment regime of patients. Furthermore, re-classification 
of patients with basal-like tumors using this approach showed better outcome than the previous 
classifications that were based on expression patterns alone. This study also re-iterated the nexus 
between certain high-level amplifications and reduced survival duration. Specifically, the study 
identified 66 genes whose expression levels correlated with copy number and patient survival 
suggesting their utility as therapeutic targets - nine genes (FGFR1, IKBKB, ERBB2, PROCC, 
ADAM9, FNTA, ACACA, PNMT, and NR1D1) are currently considered druggable. Furthermore, 
an association between low-level CNAs and upregulation of RNA and protein metabolic genes 
that contribute towards cancer progression was established using this comprehensive approach. 
Thus, integrative analysis of genomic alterations and transcription profiles has the potential to 
reveal important genes and clinical associations with prognostic, diagnostic and therapeutic 
implications in cancer. 
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 In the following chapters of this thesis, I will describe how we have developed and 
applied novel integrative concepts for mining genomic and transcriptomic data to uncover cancer 
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Chapter 2: Integrating Genomic Analysis and Experimental Methodology to 
Uncover Tumor Suppressor Genes in Nasopharyngeal Carcinoma 
 
2.0       Nasopharyngeal carcinoma (NPC) and evidence for tumor suppressor gene activity 
Nasopharyngeal carcinoma (NPC) is a rare form of cancer that originates from the 
epithelium of the nasopharynx and is generally associated with poor patient prognosis [42]. NPC 
has the highest occurrence in Southern China, and the prevalence of this disease particularly 
among the Cantonese Chinese suggests that there may be a genetic predisposition to NPC[43]. 
While Epstein-Barr virus (EBV), diet and environmental factors are thought to contribute to NPC 
progression [44, 45], the molecular events that lead to NPC are very poorly understood. Several 
cytogenetic studies involving NPC specimens have reported frequent chromosomal aberrations 
and loss of heterozygosity at 3p, 9p, 11q, and 14q [46-49]. It has been hypothesized that the 
inactivation of tumor suppressor genes (TSGs) present in these chromosomal regions may 
contribute directly to NPC progression. TSG activity at 11q13 has been observed in several other 
cancers types. Notably, the MULTIPLE ENDOCRINE NEOPLASIA type I (MEN1) gene has 
been mapped and cloned from this region [13, 50].  However, MEN1 expression does not affect 
growth of NPC cell lines[51]. TSG activity at 11q22-23 has also been observed in several 
cancers such as melanoma[52], breast[53], ovarian[54], lung[55], cervical[56], bladder[57], 
colorectal[58], and prostate cancer[59]. A novel TSG, TUMOR SUPPRESSOR IN LUNG 
CANCER 1 (TSLC1), located in this region has been identified in non-small cell lung cancer by 
functional complementation[60]. However, a role for TSLC1 in NPC progression has not been 
clearly defined [61]. Finally, molecular and cytogenetic analyses have also revealed extensive 
losses at 11q22-24 in NPC[62] but no strong candidate TSGs from this region have yet been 
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proposed. Together, these findings suggest that one or more TSGs located on chromosome 11q 
play a critical role in NPC development.  
 
2.1   Microcell-mediated chromosome transfer and discovery of chromosome-specific 
TSGs. 
Microcell-Mediated Chromosome Transfer (MMCT) (also known as somatic cell 
hybridization) is a chromosomal transfer technique developed for the identification of disease-
bearing chromosomes [63, 64]. The MMCT procedure begins with a series of sub cellular 
manipulations designed to generate single-chromosome bearing microcells derived from a donor 
cell line. The chromosome-bearing microcell can then be fused to a recipient cell line, which can 
be further selected for cell hybrids that contain the chromosomes of interest, or in some cases, a 
phenotype of interest [65]. In the context of cancer, where it may be hypothesized that a 
particular chromosome or chromosomal fragment harbors a tumor suppressor gene, a functional 
complementation approach can be taken. MMCT can be used to introduce ―normal" 
chromosomal DNA into a malignant cell lacking the chromosomal DNA of interest followed by 
screening for reversion of the tumorigenic phenotype [65, 66]. 
  
In the current work, our collaborators previously used MMCT to introduce an intact 
chromosome 11 into a tumorigenic NPC cell line referred to as HONE1, generating a number of 
―hybrid‖ cell lines that exhibited a suppression of tumorigenicity when passaged in nude 
mice[51]. Presumably, the intact chromosome 11 was able to complement the tumor suppressive 
functions of the defective chromosome 11 of the host cell. Our collaborators then observed that 
these hybrid cells remained non-tumorigenic for approximately three months, at which point they 
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regained tumorigenic behavior. These tumorigenic cells, termed ―segregants‖, thus exhibited a 
delayed latency period in tumor formation compared with that of the parental HONE1 cells [67] 
(Figure F2.1). The delayed tumor appearance was presumably the result of loss or inactivation of 





































Figure F2.1: Experimental strategy for identifying TSG-bearing chromosomal regions.  
 
The diagram explains the strategy used for deriving hybrid and segregant cell lines from the 
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2.2       MMCT with a genomic twist  
Several tumor segregant cell lines were isolated from the mice and cultured for genetic 
analysis of chromosome 11. Using detailed comparative BAC FISH and microsatellite marker 
analyses of non-tumorigenic hybrid and tumor segregant cell lines, critical genomic regions lost 
in nasopharyngeal carcinoma (NPC) were identified including a 1.8 Mb region at chromosome 
band 11q13  and three other regions of 0.36 Mb, 0.44 Mb, and 0.3 Mb at 11q22-23 [51, 67]. 
 
 While these ―critical regions‖ were consistently deleted from the segregant cell lines, the 
tumor suppressor gene(s) driving the observed phenotypes could not be readily deduced as 
greater than 100 known genes mapped to these critical regions. We sought to address this 
problem with expression microarray analysis. We hypothesized that while the expression of all 
genes localized to the critical regions would be suppressed (or absent) in the parental line and 
segregants, the key tumor suppressor gene(s) would be transcriptionally active in the non-
tumorigenic hybrid lines. Thus, we posited that the ―signature‖ of a tumor suppressor gene 
should comprise of the consistent inactivation of expression in the both the parental HONE1 
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2.3       RESULTS 
2.3.1       Microarray analysis in HONE1 cells, hybrids and tumor segregants 
Using a 19K oligonucleotide expression microarray containing probes to most human genes 
and all known genes on chromosome 11q, gene expression profiles of parental, hybrid and 
segregant cell lines were analyzed by competitive hybridization. Specifically, mRNA of the 
tumorigenic parental HONE1 line was hybridized against each of four independent (non-
tumorigenic) hybrid lines (HK11.8, HK11.12, HK11.13, and HK11.19), and each of the four 
hybrid lines was hybridized against its corresponding tumor segregant (HK11.8-3TS, HK11.12-
2TS, HK11.13-1TS, and HK11.19-4TS). A diagram of the experimental strategy is shown in 
Figure F2.2A & F2.2B. As each hybridization experiment was performed in duplicate (i.e., in 



























Figure F2.2: Microarray comparisons and the theoretical tumor suppressor signature. 
 
A) The diagram shows the microarray strategy adapted for the experiment. The HONE1 parental 
cell line was hybridized against each of four hybrid lines (biological replicates), and in turn, each 
of the hybrid lines was hybridized against its corresponding segregant line.  
B) The indicative expression signature of a tumor suppressor gene: low expression in the 
parental cell line (PAR), activated expression in the hybrids (HYBs), and low (or absent) 
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The data was then analyzed to identify genes up-regulated in the hybrids (after chromosome 
transfer) and down-regulated in the HONE1 line and tumor segregants (after loss of chromosome 
11 material) (Figure F2.2B). Genes fitting this prescribed behavior were selected based on the 
correlation between their expression pattern and the theoretical tumor suppressor ―signature‖ 
pattern (binarized as 1=up-regulated and -1=down-regulated). Genes with a Pearson correlation 
score >0.9 were selected as top tumor suppressor candidates, regardless of their genomic 
location. In total, 24 genes met this selection criterion, one of which mapped to a critical region 
of 11q at band q22.3 (Table T2.1). This gene, named THY1, was found differentially expressed 
under our selection criteria in three out of the four hybrid-segregant pairs. The gene expression 
ratios of each duplicate experiment and the mean ratio of the duplicate experiments for the 
hybrid-parental and hybrid-segregant comparisons are summarized in Table 2. A comparison of 
the expression profile of HONE1 cells with the four hybrids, showed a nearly 2-fold increased 
expression of THY1 in all the hybrids except HK11.13 (Table T2.2). Reciprocally, the mRNA 
levels of THY1 were significantly decreased in the tumor segregants, again with the exception of 
the HK11.13-11.13-1TS comparison (Table T2.2). Thus, THY1 emerged as our top candidate 
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  GENE SYMBOL & NAME  CYTOBAND 
  SAA2 serum amyloid A1    11p15.1 
  MAP1B microtubule-associated protein 1B   5q13 
  MAP1B microtubule-associated protein 1B   5q13 
  INSIG1 insulin induced gene 1   7q36 
  SQLE squalene epoxidase    8q24.1 
  FDFT1 farnesyl-diphosphate farnesyltransferase 1   8p23.1-p22 
  ARTN artemin   1p33-p32 
  HSD17B7 hydroxysteroid (17-beta) dehydrogenase 7   1q23 
  THY1 Thy-1 cell surface antigen   11q22.3 
  SAA1 serum amyloid A2   11p15.1 
  ACAS2 acetyl-Coenzyme A synthetase 2 (ADP forming)   20q11.23 
  NFKBIA nuclear factor of kappa light polypeptide gene enhancer in B-cells     
  inhibitor, alpha 
  14q13 
  FLJ36031 hypothetical protein FLJ36031   7q22.2 
  TRAF1 TNF receptor-associated factor 1   9q33-q34 
  STARD4 START domain containing 4, sterol regulated   5q22.2 
  GCH1 GTP cyclohydrolase 1 (dopa-responsive dystonia)   14q22.1-q22.2 
  CNTNAP1 contactin associated protein 1   17q21 
  Homo sapiens mRNA; cDNA DKFZp686B15184 (from clone   
  DKFZp686B15184 
  -- 
  CDKN2D cyclin-dependent kinase inhibitor 2D (p19, inhibits CDK4)   19p13 
  CTSS cathepsin S   1q21 
  CYP51A1 cytochrome P450, family 51, subfamily A, polypeptide 1   7q21.2-q21.3 
  C14orf1 chromosome 14 open reading frame 1   14q24.3 
  IL3RA interleukin 3 receptor, alpha (low affinity)   Xp22.3 
  MCFP mitochondrial carrier family protein   7q21.13 
 
Table T2.1: Top TSG candidates.  
Shown are the genes most highly correlated with the theoretical TSG expression signature, THY-
1 cell surface antigen mapping to the 11q22.2 critical region is shown in red. 
 




















*The expression ratio for duplicate “dye-swap” arrays are shown: Cy5/Cy3 and Cy3/Cy5. 
For the Cy3/Cy5 dye-swap, the reciprocal expression ratio is shown. 
 
 
Table T2.2: Expression ratios of THY1. 
 
The expression ratio is equivalent to fold-change; ratios >1 indicate higher expression in the 
hybrids, while ratios <1 indicate lower expression in the tumor segregants (TS). Note that a ratio 






Cell lines Expression ratios* 
Cy5/Cy3      Cy3/Cy5 
Average 
ratio 
11.8/HONE1 1.8702 2.7533 2.3 
11.8-3TS/11.8 0.5686 0.5537 0.56 
11.12/HONE1 2.3329 2.6434 2.5 
11.12-2TS/11.12 0.4578 0.4509 0.45 
11.13/HONE1 0.7835 1.4379 1.1 
11.13-1TS/11.13 0.8892 1.058 0.97 
11.19/HONE1 2.0286 1.9872 2.0 
11.19-4TS/11.19 0.4820 0.5696 0.53 
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2.3.2       Real-time PCR confirmation of THY1 expression patterns 
To confirm the microarray findings, THY1 expression levels were analyzed by real-time 
(RT)-PCR (Figure F2.3). RT-PCR is considered a much more quantitative measure of mRNA 
levels than microarray analysis (where seemingly small changes in expression levels by 
microarray can be, in reality, infinitely large as detected by RT-PCR). Quantification of THY1 
expression revealed a good correlation between the changes observed in the microarray 
experiments and the RT-PCR results. First, no expression of THY1 was detected in the HONE1 
cells, and THY1 expression appeared to be absent in an additional three NPC cell lines, HK1, 
CNE1, and HNE1. Second, consistent with the microarray results, THY1 was transcriptionally 
activated in the hybrids HK11.8, HK11.12, and HK11.19, but not in HK11.13. Finally, again 
consistent with the microarray observations, when comparing THY1 expression between the 
hybrids HK11.8, HK11.12, and HK11.19 and their corresponding tumor segregants, RT-PCR 
revealed consistent loss of THY1 expression in the tumor segregants (Appendix I 1.2).  
 
2.3.3        Protein analysis of THY1 in NPC 
Next, THY1 protein levels were assessed by western blot (Figure F2.4). Similar to the 
findings from RT-PCR, HONE1, HK1, CNE1, and HNE1 did not express THY1 protein, while 
protein was observed in the hybrids HK11.8, HK11.12 and HK11.19, as well as the chromosome 
11 donor cells (MCH556.15). Interestingly, the HK11.13 hybrid, which did not express 
detectable levels of THY1 mRNA, did express a low but detectable level of THY1 protein. 
Additionally, THY1 protein was not detectable in all four tumor segregants. Thus, the protein-
level analysis of THY1 expression is largely concordant with the real-time PCR results 
(Appendix I 1.6).  

















Figure F2.3: Real-time PCR analysis of THY1.  
 
Real-time PCR analysis of THY1 mRNA levels in the parental (HONE1), hybrid and segregant 
lines; 3 additional NPC lines (HK1, CNE1, HNE1); the mouse chromosome 11 donor cell line, 
MCH556.15, overexpressing THY1 (positive control); and the mouse cell line A9 (negative 
control). The DNA ladder (L) indicates the sizes of the PCR bands, which are shown on the right 










Figure F2.4. Western blot analysis of THY1. 
 
The sizes of protein bands are indicated on the right. -tubulin was used as an internal control. 
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2.3.4       THY1 promoter methylation in NPC cell lines  
Notably, the 11q22.3 critical region harboring THY1 was neither deleted in the parental 
HONE1 cells, nor several other NPC cell lines examined (data not shown). To determine the 
inactivation mechanism of THY1 in NPC, we studied the methylation status of the THY1 
promoter in the four NPC cell lines by methylation-specific PCR (MSP) analysis. Figure F2.5A 
shows the detection of methylated sequences in HONE1, HK1, CNE1 and HNE1 cells, while a 
lesser extent of unmethylated signal was observed in the HONE1 and CNE1 cell lines (Appendix 
I 1.4). Subsequent re-expression of endogenous THY1 in HONE1 cells was observed after 
treatment with the demethylating agent 5-aza-2‘-deoxycytidine (Figure F2.5B). Together, these 





























Figure F2.5. THY1 methylation profiles. 
 
A) MSP analysis of THY1 promoter methylation in four NPC cell lines (HK1, CNE1, HNE1, and 
HONE1), MCH556.15, and the universal methylated DNA (positive control). Sizes of PCR 
products are shown on the right. A methylated allele was observable in all four NPC cell lines. 
B)  Re-expression of endogenous THY1 in HONE1 cells after treatment with 5 M 5-aza-2‘-
deoxycytidine detected by RT-PCR. 
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2.3.5     Analysis of THY1 expression variation in human NPC samples 
To investigate the natural variation of endogenous THY1 expression in human 
nasopharyngeal carcinoma, we analyzed seventy clinical patient samples of NPC and nine 
samples of noncancerous nasopharyngeal mucosa for expression of THY1 protein by 
immunohistochemistry on a tissue microarray (TMA) (Figure F2.6A) (Appendix I 1.7 & 1.8). 
We observed that the staining index of THY1 expression in the noncancerous samples of 
nasopharyngeal mucosa showed an upper bound score of 6 or greater; therefore, we designated 
the staining index of 6-9 as the ―normal‖ baseline expression of THY1. Accordingly, a staining 
index of 1-4 was considered as reduced expression, and a staining index of 0 was considered to 
reflect absence of expression. In the 70 NPC cases, 44% (31/70) showed down-regulated 
expression of THY1, while another 9% (6/70) were scored as absent for THY1 expression. In the 
fraction of samples associated with lymph node metastasis at diagnosis, the frequency of down-
regulated/absent THY1 was 63% (17/27), significantly higher than that observed in primary NPC 
(33%) (14/43) (P < 0.05; Figure F2.6B). Thus, reduced expression of THY1 was observed to be 



























Figure F2.6. Immunohistochemical staining results for THY1. 
 
Immunohistochemical staining of THY1 in NPC TMA containing noncancerous nasopharyngeal 
mucosa, primary NPC, and lymph node-metastatic NPC.  
A) Representative staining of THY1 in normal nasopharyngeal mucosa, and tumor tissues 
showing reduced or loss of THY1 expression.   
B) The expression levels of THY1 detected in normal mucosa, primary, and metastatic NPC are 
shown.    
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2.3.6       Functional analysis of THY1 growth suppressive properties 
We next sought to functionally characterize THY1 for growth suppressive activity using colony 
formation assays. HONE1 cells were transfected in replicate (4x) with a construct 
overexpressing THY1 and neomycin resistance (pCR3.1-THY1) or the construct (with only 
neomycin resistance) alone (pCR3.1; as control). A significant decrease in the number of 
neomycin-resistant colonies was observed in the THY1 overexpressing cells as compared to those 
transfected with the vector alone (Figure F2.7). Specifically, we observed a 90% decrease in 
colony formation in the THY1 transfectants. To further test the inhibitory effect of THY1 on 
colony formation, a recently developed tetracycline-repressible transgene system [68] was 
utilized. HONE1 cells expressing the tetracycline trans-activator tTA were established, and these 
cells (HONE1-2) were then stably transfected with the tetracycline-repressible construct 
containing the THY1 sequence (pETE-BSD-THY1) or without the THY1 sequence (pETE-BSD) 
(Appendix I 1.10). In the absence of doxycycline (a potent tetracycline derivative), THY1 protein 
was exclusively expressed in HONE1-2 cells transfected with pETE-BSD-THY1 (Figure F2.8A), 
and a significant reduction in the number of blasticidin-resistant colonies was observed (Figure 
F2.7 and 2.8A). However, with the addition of doxycycline, THY1 expression was mitigated, and 
no significant change in colony number was observed between the pETE-BSD-THY1 and pETE-
BSD transfected HONE1-2 cells (Figure F2.8B). Together, these results provide direct evidence 





















Figure F2.7. Colony formation assays with THY1 transfectants. 
 
HONE1 cells were transfected with pCR3.1-THY1 or pCR3.1, and HONE1-2 cells were 
transfected with pETE-Bsd-THY1 or pETE-Bsd in the presence or absence of doxycycline (dox). 
The colony forming ability was calculated by comparing the number of colonies in THY1 
transfectants to that of vector alone. Each treatment was performed in quadruplicate. * designates 
a significant difference from vector-alone (p < 0.005). 
 


















Figure F2.8: Growth effects of THY1 expression in a Tet-repressible system. 
 
Representative results of the colony formation assay and Western blot analysis of the THY1- 
transfected HONE1-2 cells and vector-alone transfectants. HONE1-2 cells were transfected in  
A) the absence of dox, and  
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2.4 Discussion 
Using a comprehensive oligonucleotide microarray platform, we analyzed the global gene 
expression patterns of a tumorigenic NPC cell line (HONE1), 4 independently-derived 
nontumorigenic hybrid lines (each containing an introduced normal copy of chromosome 11), 
and 4 corresponding tumorigenic segregant lines (derived from the hybrids) that share several 
critical regions of chromosome 11 deletion. We postulated that the signature of a tumor 
suppressor gene would be characterized by activated expression in the hybrids, and reduced or 
absent expression in the parental (HONE1) cells and segregants. Through correlative analysis, 
we identified a small number of genes fitting this criteria, one of which mapped to the predefined 
critical region at 11q22.3-q23. The mRNA and protein expression patterns of this gene, called 
THY1, were then validated by RT-PCR and western blot analysis. 
 
Examination of THY1 protein levels in a tissue panel comprised of 9 normal nasopharyngeal 
mucosa specimens and 70 NPC samples revealed a substantially higher level of expression in the 
normal tissues, with the majority of NPC specimens showing reduced or absent THY1 
expression. By microscopic analysis, THY1 protein was observed primarily in the cytoplasm and 
plasma membrane of the normal nasopharyngeal mucosa. The frequency of THY1 reduction or 
absence in lymph node-metastatic NPC was 74% (20/27), which is significantly higher than that 
of primary NPC (40%), suggesting that the inactivation of THY1 might also be associated with 
metastasis of NPC. Recently, THY1 has been reported to play a role in the cell adhesion 
properties of T-cells adhering to the bone marrow stroma[69], and surface expression of THY1 
was shown to enhance focal adhesions in fibroblasts[70]. That an increasing body of evidence 
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now causally implicates loss of cell adhesion in tumor progression and metastasis[71] perhaps 
reflects an inroad for THY1 into NPC pathogenesis. 
 
THY1 is a cell surface glycoprotein of 25-28 kDa[72] expressed predominantly on the 
cytoplasmic membrane of T-cells, but has also been observed in the kidney, mammary gland, 
small intestine, skin and nervous system[73]. Functionally, THY1 has been implicated as a 
trigger for several cellular processes including lymphokine release, proliferation, differentiation, 
and apoptosis[74-78]. However, the exact physiologic role of THY1 remains unknown[79]. 
 
None of the tumorigenic NPC cell lines studies including HONE1, HK1, CNE1, HNE1 and 
the tumor segregants, were found to express THY1 transcript or protein. Our data suggests that 
loss of THY1 expression in NPC cell lines may be attributed to promoter hypermethylation, as at 
least one of the alleles was methylated in all four NPC cell lines, and demethylation by 5-aza-
cytidine restored THY1 expression in HONE1 cells.  
 
Subsequent in vitro colony formation assays provided functional evidence that activation of 
wild type THY1 is sufficient to inhibit the colony forming ability of THY1-null HONE1 cells 
using both the constitutive pCR3.1 and inducible pETE-BSD vector systems. The specificity of 
the growth suppressive effect of THY1 was supported by the absence of suppression in the 
presence of dox, when the transgene was not expressed. These data thus functionally implicate 
THY1 in NPC tumor suppression.  
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One discrepant observation in our study was the apparent lack of differential expression of 
THY1 (by microarray) observed between HONE1 and the HK11.13 hybrid, and this hybrid and 
its tumor segregant (HK11.13-TS). By RT-PCR, we observed that THY1 was undetectable in 
HONE1, HK11.13, and HK11.13-1TS after 45 PCR cycles. Such absence of expression could 
explain the lack of differential expression observed by microarray analysis; subsequent analysis 
confirmed that the microarray detection levels were substantially lower in these samples (data 
not shown). Genotyping results for this particular hybrid may provide a further explanation. The 
donor chromosome loci represented by microsatellite markers D11S908 and D11S2077, which 
map close to the THY1 physical location, were observed to be absent in this particular 
hybrid[61], suggesting that the wild type THY1 gene was either not transferred to this particular 
hybrid or was lost during or shortly after completion of the MMCT procedure. Nevertheless, 
while this explains the discrepant microarray and PCR observations, it fails to explain why THY1 
protein was presumably detected in this hybrid (but not in the parental or segregant cells) by 
western blot. Further genetic and biochemical analysis will be required to resolve this question. 
 
Coincidentally, when searching the literature for clues to THY1 function, we learned of a 
study whereby MMCT was used to introduce chromosome 11 into and ovarian cancer cell line, 
SKOV-3, and hybrids showing suppressed tumorigenicity were isolated from SCID mice. Using 
a subtractive hybridization technique, where cDNA populations from the tumorigenic parental 
line were subtracted from the nontumorigenic hybrids, the authors identified THY1 as their top 
tumor suppressor candidate gene [85]. In a subsequent study, the authors showed that abrogation 
of THY1 expression in non-tumorigenic cells could restore tumorigenesis; however, both in vitro 
and in vivo growth and tumorigenicity assays showed that THY1 activation alone was not 
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sufficient to suppress ovarian cancer tumorigenicity[80], implying that other oncogenic 
mechanisms may interact with or modulate THY1 tumor suppressor function. 
 
In summary, our findings suggest that THY1 is a novel tumor suppressor gene whose loss of 
expression by deletion or promoter methylation is a common event contributing to 
nasopharyngeal carcinogenesis. That THY1 deficiency was significantly associated metastatic 
NPC suggests a possible role in NPC progression, and a clinical utility for THY1 in patient 
prognosis. While further work is needed to characterize the precise molecular functions of THY 
in carcinogenesis, it should not be overlooked that a number of other genes mapping to various 
alternative chromosomal regions also matched the expression criteria of the theoretical tumor 
suppressor gene signature. How these genes may interact with THY1 function, or contribute to 
tumor suppression independent of THY1 function is an important question that we address in the 
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Chapter 3: Holistic Effects of MMCT: A Combinatorial Analysis of the NPC 
Altered Cancer Genome 
 
3.0 Reconstructing the MMCT hypothesis 
Mapping of tumor suppressor genes by MMCT-driven functional complementation 
involves the introduction of chromosomal material into a tumorigenic cell line, selection of 
nontumorigenic hybrids, and subsequent detailed chromosomal analysis of hybrid-derived tumor 
segregants. In this strategy, the tumor suppressor hypothesis is predicated on the assumptions: 1) 
that the introduced chromosome harbors one or more TSGs that act directly to suppress 
tumorigenicity in the hybrid, and 2) that the subsequent reversion to the tumorigenic phenotype 
(i.e., the segregant) results from loss of one or more TSGs on the introduced chromosome.  
In this work, we investigate the alternative hypothesis: that genes functionally 
contributing to the phenotypes of tumor suppression and reversion may stem from genomic 
alterations that occur outside of the introduced chromosome. Below, several plausible models 
aligned with this hypothesis are enumerated. 
1. A gene present on the introduced chromosome could activate a TSG located on an 
endogenous chromosome (resulting in a nontumorigenic hybrid), and this endogenous 
chromosomal region could be subsequently reduced in copy number (resulting in a tumorigenic 
segregant). 
2. A gene present on the introduced chromosome could inactivate an oncogene located on 
an endogenous chromosome (resulting in a nontumorigenic hybrid), and this endogenous 
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chromosomal region could be subsequently increased in copy number augmenting the activity of 
the oncogene (resulting in a tumorigenic segregant). 
3. A TSG present on an endogenous chromosome could become activated by 
amplification during the MMCT procedure (resulting in a nontumorigenic hybrid), and this 
endogenous chromosomal region could be subsequently reduced in copy number (resulting in a 
tumorigenic segregant) with or without involvement of the introduced chromosome. 
4. An oncogene present on an endogenous chromosome could become deactivated by 
copy number loss during the MMCT procedure (resulting in a nontumorigenic hybrid), and the 
same or different oncogene-harboring chromosomal region could be subsequently amplified 
(resulting in a tumorigenic segregant) with or without involvement of the introduced 
chromosome. 
Several previous experimental observations also lend support to the possibility of the 
alternative hypothesis. First, while we identified THY1 at 11q22.3 as a candidate tumor 
suppressor based on the original premise that an 11q critical region should harbor a TSG, we 
observed that one hybrid line (HK11.13) failed to express THY1. Microsatellite analysis 
suggested a genetic deletion of the gene prior to, or during, the MMCT procedure. This indicates 
that 1) unexpected chromosomal alterations can occur in the MMCT process, and 2) alternate 
tumor suppression mechanism may explain the ―loss of tumorigenicity‖ phenotype. Furthermore, 
our whole-genome microarray expression analysis identified a number of genes residing on 
different chromosomes that also displayed the theoretical tumor suppressor signature of reduced 
expression in the hybrids, and increased expression in the parental and segregant lines (Chapter 
2, Table T2.1). 
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3.1       Mining expression data for structural alterations 
 While by conventional MMCT it would not be possible to assess the comprehensive 
milieu of structural alterations in the parental, hybrid and segregant genomes, we postulated that 
a method of genome-wide locus-specific expression analysis may provide evidence for the 
existence of other recurrent chromosomal alterations that might explain the observed phenotypes. 
This idea is based on the concept that genes within a given amplified chromosomal region 
would be significantly enriched for relative overexpression, while genes located within a 
deleted chromosomal region would be significantly enriched for relative underexpression. 
To investigate this possibility, we developed a novel computational strategy involving the 
mapping of gene expression data to known chromosomal positions followed by density plot 
analysis based on the direction of gene expression (up or down) in parental-hybrid and hybrid-
segregant comparisons. These plots were then used to visually and statistically identify candidate 
recurrent copy number alterations (CNAs) within the genome by determination of the most 
prominent density ―peaks‖ and ―troughs‖. Candidate CNAs resulting from this analysis were 
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3.2 RESULTS  
3.2.1 Data acquisition and processing 
As shown in Chapter 2, Figure 2, we used an oligonucleotide microarray representing 
19,000 genes to compare gene expression levels between: 1) HONE1 parental cells and each of 
four non-tumorigenic hybrids (11.8, 11.12, 11.13 and 11.19), and 2) each hybrid and its 
corresponding tumor segregant (11.18-3TS, 11.12-2TS, 11.13-1TS and 11.19-4TS). Dye-swap 
experiments (whereby two RNA samples are competitively hybridized to duplicate arrays, with 
the Cy3 and Cy5 sample labeling scheme being reversed between the two arrays) were carried 
out to control for dye labeling biases according to conventional practice (Appendix I 1.1). 
Normalized gene expression ratios were then log transformed, and the reciprocal ratios were 
taken from one array in the dye-swap pair and used to compute the average ratios for the two 
replicate experiments (Chapter 2, Table T2.2). Thus in practice, for each comparison, average 
expression ratios >1.0 were considered ―overexpressed‖ in the hybrids, while ratios <1.0 were 
considered overexpressed in the HONE1 cells or segregants (depending on the comparison). 
Finally, as our aim was to uncover endogenous CNAs that might better explain the phenotypic 
observations than the chromosome-11-centric theory, we averaged the gene expression ratios 
across biological replicates (i.e., 4 replicates of parental (tumorigenic) versus hybrid (non-
tumorigenic), and 4 replicates of hybrid versus tumorigenic segregant). This final averaging step 
allowed the gene expression data to be distilled down to a single quantitative measurement: >0 
indicating increased expression in the hybrids, <0 indicating reduced expression in the hybrids 
(relative to HONE1 and segregant lines). 
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3.2.2 Characterizing genomic-expression density (GED) plots 
 To map the microarray expression data back to the genome, we traced the oligonucleotide 
probe sequences to GenBank accession numbers, and then mapped the GenBank sequences to 
the curated genome using the UCSC genome browser (http://genome.ucsc.edu/). Each gene was 
assigned two values: 1) the average expression value of the parental versus hybrids (PvH) 
comparison, and 2) the average expression value of the hybrids versus segregants (HvS) 
comparison. A sliding window of 5 MB size was initially selected for density plotting, as a 
window of this size was estimated to be sufficient for detecting known regions of deletion on 
chromosome 11 in the segregants. Genes within the window at a particular slide position were 
analyzed for the enrichment of up-regulated or down-regulated gene expression. By convention, 
in our genomic-expression density (GED) plots the enrichment of down-regulated genes (in the 
parental or segregant lines) corresponded to a high score (near to 1.0); equal distribution of up- 
and down-regulated genes corresponded to a ―baseline‖ value of ~0.5, and enrichment of up-
regulated genes corresponded to a score near to 0. All chromosomes were scanned using the 5 
MB window sliding at one-gene intervals, and peaks that achieved values above 0.7, or troughs 
that reached values below 0.3, were chosen for statistical analysis by Fisher‘s exact test to 
determine the significance of the distribution of up- or down-regulated genes in that region.  
 
Figure F3.1A shows a representative genomic-expression density (GED) plot for 
chromosome 15, which lacks evidence of copy number changes. Neither the PvH (in orange) nor 
the HvS (in green) GED plots showed enrichment fluctuations above 0.7 or below 0.3. For 
chromosome 11, however, several interesting regions emerged. Two distinct regions at 11q13.4-
14.1 and 11q21-23.3 were found to be enriched for up-regulated gene expression in the hybrids 
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(PvH plot) and down-regulated gene expression in the segregants (HvS plot) consistent with a 
―phenotypically-balanced‖ event (i.e., a copy number gain in the hybrid, with subsequent copy 
number loss in the segregant) (Figure F3.1B). Statistical analysis suggested that these 
observations would, individually, be unlikely to occur by chance (11q13.4-14.1, P=0.0008 
[PvH], P=0.006 [HvS]; 11q21-23.3, P=0.000009 [PvH], P=0.0002 [HvS]). Notably, the 
previously described THY1 cell surface antigen gene we identified as a novel tumor suppressor in 
NPC is located in the 11q22.3 region (Chapter 2). Both microsatellite and FISH analysis of 
11q13.4-14.1 and 11q21-23.3 in the segregant cell lines previously established a consistent loss 
of heterozygosity in both regions [67]. Thus, the GED plot analysis correctly identified two 
chromosomal regions known to display copy number gain in the hybrids and subsequent copy 
number loss in the segregants. 
 
The 11p15.1-14.1 locus was also identified here as a candidate region of copy number 
loss in the segregants (P=0.002; Figure F3.1B). Interestingly, while this region has not been 
previously analyzed by microsatellite or FISH analysis in our NPC segregants, it has been 
implicated as a tumor suppressor locus elsewhere, showing loss of heterozygosity (LOH) in 
several adult and childhood cancers [81].  
 
 A detailed GED plot analysis of the whole genome revealed evidence for several other 
phenotypically-balanced recurrent alterations. In chromosome 1, two adjacent loci located at 
1q23.3-23.5 and 1q32.1-31.2 showed evidence of copy number gain in the hybrids (P=0.002, 




, respectively) (Figure 
F3.2A). Interestingly, loss of chromosome 1q23 was recently reported to play a role in the 
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initiation and progression of insulinomas and esophageal squamous cell carcinomas [82]. In 
chromosome 16, two interesting loci located at 16q12.2 and 16p13.3-13.2 were identified as 
candidate recurrent CNAs (Figure F3.2B). The 16q12.2 region appeared to only be amplified in 
the segregants (P=0.0006), while 16p13.3-13.2 appeared more ―phenotypically balanced‖ with 





 [HvS]). Notably, in a recent study of breast cancer copy number 
alterations, 16p13 was observed to be amplified in over half of the tumors studied [83]. The 
















































Figure F3.1: Genomic-expression density plots.  
 
A) Representative GED plot of the averaged expression data for chromosome 15.  
B) GED plot of Chromosome 11. Peaks (>0.7) and troughs (<0.3) represent loci where genes are 
disproportionately down- or up-regulated. Green peaks reflect local down-regulated expression 
in the segregants (relative to hybrids), and orange peaks represent local down-regulated 
expression in the parental cells (relative to hybrids).) The statistical significance of peaks and 
troughs was calculated using Fisher‘s exact test; p-values are shown in corresponding color 
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Figure F3.2: GED plots of (A) Chromosome 1 and (B) Chromosome 16.  
 
Peaks (>0.7) and troughs (<0.3) represent loci where genes are disproportionately down- or up-
regulated. Green peaks reflect local down-regulated expression in the segregants (relative to 
hybrids), and orange peaks represent local down-regulated expression in the parental cells 
(relative to hybrids).) The statistical significance of peaks and troughs was calculated using 
Fisher‘s exact test; p-values are shown in corresponding color above peaks and below troughs. 
Chromosomal bands of interest are shown at the top. 
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3.2.3       Confirmation by Quantitative real-time PCR 
Quantitative real-time (RT) PCR was used to confirm the microarray/GED plot findings of 
locus-specific differences in gene expression between hybrids and their respective segregants 
(Appendix I 1.12). At each locus, a panel of genes was analyzed for expression differences. 
Analysis of genes located in both the 1q23.3-23.5 region and the 1q32.1-31.2 locus showed a 
considerable and consistent decrease in transcript levels in the segregants (Figure F3.3A & 
3.3B), consistent with the GED plot data. Conversely, RT PCR analysis of genes at chromosome 
16p13.3-13.2 showed a substantial and consistent increase in transcript levels in the segregants 
(Figure F3.4). Thus, quantitative PCR analysis of gene transcript levels corroborates the 







































Figure F3.3: Quantitative PCR of the genes in Chromosome 1 (11.8 hybrid).  
 
A) Genes from the 1q23.3-23.5 locus and  
B) genes from the 1q32.1-31.2 locus are shown. The histogram shows the average fold 
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Figure F3.4: Quantitative PCR of the genes of Chromosome 16p13.3-13.2 in 11.8. 
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3.2.4       Cytogenetic validation of the GED plot analysis 
 Two of the four hybrid-segregant pairs of cell lines were available to investigate the 
accuracy of the whole-genome GED plot analysis in uncovering novel recurrent CNAs. Using 
FISH and SKY methodologies, several candidate regions identified by the GED plot were 
investigated. FISH analysis was performed using a panel of probes mapping to the regions of 
interest (Table T3.1) (Appendix I 1.13 & 1.14). As described below, for both of the hybrid-
segregant pairs, the cytogenetic results were highly consistent with the GED plot observations. 
At chromosome 1q23.3-23.5 and 1q32.1-31.2, 5/7 probes and 4/6 probes, respectively, showed a 
clear and consistent loss of either one or two copies in the segregants (relative to the hybrid) 
(Table T3.1 and Figure F3.5). Those two probes from each region did not show a copy number 
change indicates that the loss of heterozygosity may not be contiguous (Table T3.1). 
 
Similarly, chromosome position 16p13.3-13.2 showed an increase in copy number in the 
segregant (relative to the hybrid) (Figure F3.5). Along the chromosome at 1q23.3-23.5 most of 
the probes showed consistent loss of either one or two copies and intermittently some of the 
probes didn‘t gain or lose any copy number indicating again that the loss is not completely 
contiguous. The chromosome 16p13.3-13.2 region is relatively small, and all the probes that 
were tested showed the same increase in copy number (Table T3.1). SKY analysis of the hybrids 
consistently revealed the presence of nearly 7 copies of chromosome 1, out of which only three 
were found to be intact, while the rest were truncated and often fused with fragments from other 
chromosomes (Figure F3.5, lower panels). In the segregant lines, SKY analysis revealed a 
consistent loss of one or two copies of chromosome 1. Chromosome 16, on the other hand, 
showed four copy numbers in both hybrids and segregants, with the exception of a fragment of 
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chromosome 16 found translocated to chromosome 8 only in the segregants. This translocated 
piece could account for the consistent single copy gain in the segregants. Taken together, these 
observations suggest that the GED plot analysis, which uses only transcriptional information to 
measure genome-localized expression fluctuations (i.e., consistent with copy number gains and 
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Probes(Chr1q23.3) Hybrid Segregant Loss Start Stop 
RP11-79M15 6 6 0 157484198 157580781 
RP11-154F13 6 4 2 165964956 166136565 
CTD-2171O24 6 4 2 166048311 166122915 
CTD-2166B20 6 4 2 167346697 167442066 
CTD-3226D17 6 6 0 159490628 159517234 
RP11-18E13 6 5 1 175377432 175553514 
RP11-152A16 6 4 2 175804858 175986939 
 
Probes(Chr1q32.1) Hybrid Segregant Loss Start Stop 
CTD-2501I18 6 4 2 9057132 9208284 
CTD-2332F8 6 6 0 1.97E+08 1.97E+08 
RP11-284G5 6 4 2 2.01E+08 2.01E+08 
CTD-2288C12 6 6 0 2.02E+08 2.02E+08 
RP11-243A2 6 5 1 2.05E+08 2.05E+08 
RP11-22D13 6 5 1 2.09E+08 2.09E+08 
 
Probes(Chr16p13.3) Hybrid Segregant Gain Start Stop 
CTD-2252G4  4 5 1 11227 131219 
RP11-243K18 4 5 1 266994 431803 
RP11-64L12 4 5 1 535529 715973 
RP11-31I10 4 5 1 1752997 1918786 
RP11-626F12 4 5 1 2825861 3016463 
RP11-95P2 4 5 1 4114617 4289638 
CTD-3103H12 4 5 1 4488744 4545592 




Table T3.1: List of FISH probes, their copy number status in hybrids and segregants, and 
their position in the genome are provided.  
 
A) Probes from chromosome 1q23.3-23.5 locus.  









































Figure F3.5: FISH and SKY results of NPC hybrid and segregant lines. 
 
White arrows indicate the signals in chromosome 1; yellow arrows mark the signals in 
chromosome 16. SKY images are shown below the FISH results.  
A) hybrid (11.8) and segregant names (11.8_ts) and B) hybrid (11.19) and segregant names 
(11.19_ts). 
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3.3 Discussion 
In this work, we have challenged the age-old assumption that TSG discovery by MMCT-
based functional complementation should focus only on genes located within the exogenously 
introduced chromosome. By conducting a systematic genomic analysis of locus-specific 
differential gene expression between HONE1, hybrid, and segregant cells (i.e., by GED plot 
analysis), we have elucidated a number of candidate recurrent copy number alterations that we 
suspect harbor one or more genes contributing to the observed tumor phenotypes. Known 
alterations on chromosome 11 served as a positive control in our model, demonstrating that 
genomic-expression density plot analysis can accurately discover underlying chromosomal 
imbalances distinguished by locus-specific imbalances in gene expression.  
 
Several of the phenotypically-balanced candidate loci were examined in detail by 
quantitative real time PCR as well as the cytogenetic methods, FISH and SKY. Two adjacent 
regions on chromosome 1, 1q23.3-23.5 and 1q32.1-31.2, showed evidence of copy number gain 
in two hybrids and subsequent copy number loss in the two corresponding segregant lines, while 
the p13.3-13.2 locus on chromosome 16 showed evidence of copy number loss in the hybrids 
followed by copy number gain in the corresponding segregants. Due to political constraints 
encountered by our collaborators, we have thus far only been able to validate several of our 
candidate CNAs, in only two of the four hybrid-segregant pairs (and not including the original 
HONE1 parental line). However, for future publication of this work, this problem will be 
rectified; we are already preparing to extend the cytogenetic analysis of these loci to the 
remaining hybrid-segregant pairs and the original HONE1 parental cells. Furthermore, we also 
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will examine cytogenetically the 11p15 region suspected to be deleted in the segregants, as well 
as several other candidate regions of phenotypically-unbalanced copy number gain. 
 
HONE1 nasopharyngeal carcinoma cells are hypo-tetraploid with a large number of both 
segmental and whole-chromosome imbalances. As shown in Fig. 5, the copy number losses at 1q 
and copy number gain at 16p (observed in the segregants) are more representative of subtle 
dosage effects, rather than homozygous allelic deletion or high-level amplification. Nevertheless, 
their detection by averaged expression levels across four biological replicates (parental to 
hybrid, and hybrid to segregant) and their cytogenetic validation in two of the replicates, indicate 
that these alterations, though subtle, are recurrent in our experimental model and thus consistent 
with a role in mediating the observed tumorigenic phenotypes.  
 
By RT-PCR analysis, we examined the impact of the CNAs on local gene expression. We 
found that the average gain in gene expression at 16p13.3-13.2 was approximately 13-fold higher 
in the segregants relative to the hybrids. Conversely, at 1q23.3-23.5, the average reduction of 
gene expression in the segregants was roughly 4-fold lower relative to the hybrids. Thus, while 
the copy number differences appeared subtle, the impact on gene expression was more 
substantial, with fold differences that we postulate could manifest in the observed phenotypic 
differences. 
 
The alterations discovered at 1q best fit model #3 of the alternative hypothesis described 
in the first section of this chapter: that a TSG present on an endogenous chromosome could 
become activated by amplification during the MMCT procedure (resulting in a nontumorigenic 
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hybrid), and this endogenous chromosomal region could be subsequently reduced in copy 
number (resulting in a tumorigenic segregant) with or without involvement of the introduced 
chromosome. In this case, our data suggest that endogenous TSG(s) reside on the identified 1q 
regions, and that the hybrid cells gain copies of these regions during chromosomal 
transfer/hybrid generation by either amplification or clonal selection. The clonal selection theory 
can be explained by a subpopulation of HONE1 cells characterized by increased copy number at 
the 1q regions and thus, presumably associated with enhanced potential for TSG activation. In 
the presence of exogenous chromosome 11, this subpopulation may have a selective advantage 
for giving rise to a nontumorigenic phenotype. Reciprocally, the TSG activity would become 
suppressed as the hybrids lose copies of these 1q regions during progression towards the 
segregant phenotype. In the case of 16p, a reduction in copy number was associated with hybrid 
formation, while a gain in copy number was associated with progression to a segregant 
phenotype. This phenomenon is most related to model #4, whereby an oncogene present on an 
endogenous chromosome could become deactivated by copy number loss during the MMCT 
procedure (resulting in a nontumorigenic hybrid), and the same oncogene-harboring 
chromosomal region could be subsequently amplified, augmenting the activity of the oncogene, 
(resulting in a tumorigenic segregant). Again, the clonal selection theory may be invoked. In this 
case, a HONE1 subpopulation with reduced copy number of a 16p13.3-13.2-localized oncogene 
(and thus suppressed oncogenic activity) could selectively give rise to a nontumorigenic hybrid. 
Hybrid clones could then progress towards the segregant phenotype by reactivation of the 
oncogene through selective amplification. 
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An interesting question is whether one chromosomal locus is alone sufficient to drive the 
tumor suppression (hybrid) and reversion (segregant) phenotypes. Previously, we identified 
THY1 at 11q22.3 as a candidate tumor suppressor gene in our model of NPC tumorigenicity. We 
observed that THY1 expression could modulate the growth properties of NPC cells in a manner 
consistent with a role in tumor suppression. However, that multiple other chromosomal changes 
were repeatedly selected for in our ―parental-hybrid-segregant‖ replicates, suggests that each 
recurrent locus, together with THY1, plays a necessary role in a larger and more complex 
tumorigenic program than can be explained by the activity of a single gene. 
 
In conclusion, our results suggest that GED plot analysis can shed light on previously 
unanticipated recurrent copy number changes in endogenous chromosomes that may contribute 
to the tumor suppression/reversion phenotypes. While our data implicate a small number of 
specific genomic modifications, they neither tell us which specific genes or pathways are being 
selected for, nor how they interact with elements of chromosome 11. In the following chapter, 
we seek to better understand the biology behind our observations by building on the copy 
number-gene expression intersect with integration of a third tier of information: pathway 
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Chapter 4: Oncogenomics and Pathway Discovery in NPC Progression 
 
4.0       From genomic alterations to signaling pathways 
 In the previous chapters, we have used an MMCT-based functional complementation 
approach to model how tumorigenic properties of NPC cells are lost and gained from a genomic 
perspective. While the introduction of chromosome 11 conferred a nontumorigenic phenotype to 
hybrid cells, and specific losses of chromosome 11 were associated with reversion to the 
tumorigenic phenotype, other phenotype-correlated recurrent CNAs were also observed, 
implying the existence of a complex interplay between multiple genes and tumorigenicity. In this 
work, we sought to gain insight into NPC tumorigenicity from a pathway perspective, rather than 
a purely genomic one. We revisited the question of a ―tumor suppressor signature‖ presented in 
Chapter 2, where we identified genes whose expression patterns varied according to phenotypic 
state. Genes up-regulated in the hybrids (relative to parental) and down-regulated in the 
segregants (relative to hybrids) were of primary interest. Here, we also considered genes with the 
reciprocal pattern (up in parental cells relative to hybrids, and down in hybrids relative to 
segregants) for a comprehensive assessment of all differentially expressed genes in our model of 
tumorigenicity.  
 
 In the following chapter, we describe in detail how the application of a statistical gene 
ontology analysis to sets of differentially expressed genes revealed the involvement of multiple 
signaling pathways, and further explore by clustering, promoter mining, and biochemical 
validation the specific involvement of sterol biosynthesis in the progression of NPC. 
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4.1       RESULTS 
4.1.1 Ontology and pathway analyses 
From the microarray experiments, differentially expressed genes were selected for each 
of the two phenotypic comparisons: Parental versus Hybrid (PvH; 827 genes) and Hybrid versus 
Segregant (HvS; 714 genes). Genes that showed at least a 1.5 fold change consistently, across all 
replicate cell-line comparisons and in the same direction, were considered to be differentially 
expressed. The differentially expressed genes were then categorized according to their direction 
of expression (i.e., up- or down-regulated) for gene ontology analysis (Table T4.1).  
 




Parental vs. Hybrid 827 442 385 
Hybrid vs. Segregant 714 387 327 
 
Table T4.1: Differentially expressed genes in PvH and HvS comparisons. 
 
Pathway and gene ontology analyses were carried out separately on the gene expression 
categories to identify significantly enriched functional classes of genes. We used the Database 
for Annotation, Visualization and Integrated Discovery (DAVID) tool from the National Institute 
of Allergy and Infectious Diseases (NIAID)[84], NIH for the functional annotation analysis. 
DAVID contains a knowledgebase that integrates and conglomerates the major and well-known 
public bioinformatics resources such as NCBI, PIR, SWISS-PROT, GO, OMIM, PubMed, 
KEGG, BIOCARTA, Affymetrix, TIGR, Pfam, BIND, MINT and DIP using a graph theory 
evidence-based ―DAVID Gene Concept‖. The knowledge base is the central engine of this tool 
on which several analytical domains are based. The ―gene enrichment and functional annotation 
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analysis‖ domain of DAVID was used to analyze the gene lists for statistical enrichments of GO 
terms and KEGG and BIOCARTA pathways. A modified Fisher Exact score (more stringent 
than the classical Fisher exact score) termed ―EASE score‖ was used to statistically identify the 
significant subsets of genes associated with a particular functional term or pathway (See 
Appendix I 1.15)[85]. This analysis revealed a number of statistically significant functional gene 
enrichments within each of the gene lists examined. The results are shown in Tables T4.2-T4.5.   
 
First, we observed enrichment of a number of known cancer-related processes that 
corresponded well with the tumorigenic phenotype [86]. For example, in the HvS comparison, 
Cell Adhesion, Cell Motility, Angiogenesis, and Blood Vessel Development were all significantly 
enriched in the genes up-regulated in the tumor segregants; while Cell Adhesion, Cell Death, and 
Apoptosis were all enriched in the genes down-regulated in the segregants. Second, we observed 
that some enriched terms were ―phenotypically balanced‖, eg, down-regulated in parental (PvH) 
and also down-regulated in the segregants (HvS) – ―balanced‖ with respect to reduced 
expression in the tumorigenic phenotypes (parental and segregants). For example, just as Cell 
Adhesion, Cell Death, and Apoptosis were found enriched in the list of genes down-regulated in 
the segregants (relative to hybrids), these same processes were also enriched for in the down-
regulated genes of the parental cells (relative to hybrids). 
 
One of the most interesting and unexpected phenotypically-balanced findings involved 
steroid metabolism/biosynthesis genes. GO analyses involving the HvS down-regulated genes 
(down in segregants) revealed statistically significant Ease scores of P = 9.0E-13 and P = 3.67E-
10, respectively, for Steroid Biosynthesis and Steroid Metabolism; while Pathway analysis 
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resulted in an Ease score of P = 7.62E-9 for Biosynthesis of Steroids (Table T4.2). Reciprocally, 
GO analyses of the PvH down-regulated genes (down in parental) showed statistically significant 
enrichment for Steroid Biosynthesis and Steroid Metabolism (P = 6.0E-4 and P = 1.4E-2, 
respectively); as well as Pathway enrichment of Biosynthesis of Steroids (P = 4.66E-5) (Table 
T4.3). Consistent with these observations, the list of 24 top candidate (tumor suppressor) genes 
derived using the ―Pearson correlation coefficient‖ score-based ranking consisted of seven (i.e., 
29%) key steroid metabolism regulatory genes (Figure F4.1). Taken together, these observations 
demonstrate a significant correlation between reduced expression of steroid 
metabolism/synthesis genes and tumorigenic growth, implicating the biology of steroid 
production in the maintenance of a nontumorigenic phenotype. 
 
One subgroup of steroids, the sterols, are amphipathic lipids synthesized from acetyl-
coenzyme A – and the predominant sterol in vertebrate cells is cholesterol. Like Steroid 
Biosynthesis, Lipid Biosynthesis was also significantly enriched in the down-regulated genes of 
both the HvS and PvH comparisons (P = 9.24E-8 and P = 8.15E-3, respectively); while 
Cholesterol Biosynthesis, specifically, had an Ease score of P = 7.19E-7 (the 4
th
 most significant 
score) in the down-regulated genes of the HvS comparison. Thus, one interpretation of these 
observations is that, more specific than general steroid production, the production of sterols, and 
perhaps cholesterol, in particular, may be involved in tumor suppression. 
 
At the pathway level, TNFR2 Signaling Pathway was the second most significant 
pathway in the HvS down regulated gene list (9.69E-3) (Table T4.2 & T4.3). Interestingly, the 
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activation of this pathway is known to be associated with both tumor growth and tumor death, 













































Table T4.2: Gene ontology and pathway analysis of down regulated genes in the segregants 
showing the significantly enriched pathways and GO terms. 
Term Count  %  P Value 
BIOSYNTHESIS OF STEROIDS(Homo sapiens)       7   7%     7.62E-9   
TERPENOID BIOSYNTHESIS(Homo sapiens)        2   2%     5.3E-2   
 
Term Count  %  P Value 
STEROID BIOSYNTHESIS        13   14%     9.0E-13   
STEROID METABOLISM        14   15%     3.67E-10   
LIPID BIOSYNTHESIS        14   15%     9.24E-8   
CHOLESTEROL BIOSYNTHESIS        7   7%     7.19E-7   
ALCOHOL METABOLISM        10   10%     2.96E-6   
CHOLESTEROL METABOLISM        7   7%     1.80E-4   
CELL DEATH        7   7%     3.41E-2   
DEATH        7   7%     3.55E-2   
CELL MIGRATION        3   3%     4.34E-2   
ORGANOGENESIS        10   10%     4.38E-2   
AMINE METABOLISM        5   5%     6.12E-2   
REGULATION OF CELLULAR PHYSIOLOGICAL 
PROCESS      
  7   7%     7.50E-2   
APOPTOSIS        6   6%     7.67E-2   
CELL ADHESION        7   7%     8.11E-2   
AROMATIC COMPOUND METABOLISM        3   3%     8.76E-2   
POSITIVE REGULATION OF PHYSIOLOGICAL 
PROCESS      
  5   5%     9.10E-2   
CELLULAR PHYSIOLOGICAL PROCESS        57   61%     9.88E-2   
 
Term Count  %  P Value 
TNFR2 Signaling Pathway(Homo sapiens)        3   3%     9.69E-3   
 




















Table T4.3: Gene ontology and pathway analysis of up regulated genes in the segregants 




Term Count  %  P Value 
CELL ADHESION        9   10%     3.93E-3   
DEVELOPMENT        16   18%     7.35E-3   
CELL MOTILITY        5   5%     9.17E-3   
ORGANOGENESIS        10   11%     1.73E-2   
ANGIOGENESIS        3   3%     2.05E-2   
BLOOD VESSEL DEVELOPMENT        3   3%     2.27E-2   
CELLULAR PHYSIOLOGICAL PROCESS        51   60%     3.34E-2   
TRNA PROCESSING        3   3%     4.43E-2   
REGULATION OF BIOLOGICAL PROCESS        20   23%     4.46E-2   
IMMUNE CELL MIGRATION        2   2%     5.19E-2   
POSITIVE REGULATION OF PHYSIOLOGICAL PROCESS        5   5%     5.7E-2   
 
Melanocyte Development and Pigmentation 
Pathway(Homo sapiens)      
  3   0%     4.44E-2   
Transcription Regulation by Methyltransferase of 
CARM1(Homo sapiens)      
  3   0%     4.44E-2   
 





















Table T4.4: Gene ontology and pathway analysis of down regulated genes in the parental 
cell lines showing the significantly enriched pathways and GO terms. 
 
 
Term  Count  %  P Value 
CELL-CELL SIGNALING         19   8%     5.82E-5   
CELL DEATH         17   7%     1.83E-4   
DEATH         17   7%     2.5E-4   
MAINTENANCE OF PROTEIN LOCALIZATION         4   1%     3.65E-4   
ALCOHOL METABOLISM         11   4%     5.27E-4   
REGULATION OF CELLULAR PHYSIOLOGICAL PROCESS         18   7%     5.72E-4   
STEROID BIOSYNTHESIS         8   3%     6.0E-4   
MAINTENANCE OF LOCALIZATION         4   1%     6.98E-4   
APOPTOSIS         15   6%     9.8E-4   
CELL COMMUNICATION         64   27%     9.29E-4   
CELL PROLIFERATION         26   11%     1.55E-3   
CELL ADHESION         17   7%     1.93E-3   
RESPONSE TO EXTERNAL STIMULUS         28   11%     3.36E-3   
NEGATIVE REGULATION OF PHYSIOLOGICAL PROCESS         13   5%     5.40E-3   
NEGATIVE REGULATION OF CELLULAR PHYSIOLOGICAL PROCESS         10   4%     5.89E-3   
LIPID BIOSYNTHESIS         12   5%     8.15E-3   
STEROID METABOLISM         9   3%     1.4E-2   
 
BIOSYNTHESIS OF STEROIDS(Homo sapiens)         6   2%     4.66E-5   
TERPENOID BIOSYNTHESIS(Homo sapiens)         4   1%     1.79E-4   
CALCIUM SIGNALING PATHWAY(Homo sapiens)         10   4%     1.67E-2   
CIRCADIAN RHYTHM(Homo sapiens)         3   1%     3.96E-2  
 























Table T4.5: Gene ontology and pathway analysis of up regulated genes in the segregants 
showing the significantly enriched pathways and GO terms. 
Term Count  %  P Value 
CELLULAR PHYSIOLOGICAL 
PROCESS      
  345   58%     9.71E-13   
NUCLEOBASE, NUCLEOSIDE, 
NUCLEOTIDE AND NUCLEIC ACID 
METABOLISM      
  136   23%     1.33E-7   
CELLULAR METABOLISM        255   43%     1.24E-6   
REGULATION OF BIOLOGICAL 
PROCESS      
  123   20%     6.19E-6   
TRANSCRIPTION        87   14%     1.93E-4   
CELLULAR BIOSYNTHESIS        50   8%     2.44E-4   
REGULATION OF METABOLISM        88   14%     2.93E-4   
PROTEIN METABOLISM        113   19%     3.13E-4   
RIBOSOME BIOGENESIS        8   1%     3.47E-4   
CELLULAR PROTEIN 
METABOLISM      
  112   19%     3.53E-4   
DEVELOPMENT        74   12%     5.81E-4   
RIBOSOME BIOGENESIS AND 
ASSEMBLY      
  8   1%     7.03E-4   
MACROMOLECULE METABOLISM        121   20%     1.21E-3   
NEGATIVE REGULATION OF 
METABOLISM      
  13   2%     2.22E-3   
CYTOPLASM ORGANIZATION AND 
BIOGENESIS      
  8   1%     2.64E-3   
NEGATIVE REGULATION OF 
PHYSIOLOGICAL PROCESS      
  24   4%     2.84E-3   
ORGANOGENESIS        42   7%     2.93E-3   
ORGANELLE ORGANIZATION AND 
BIOGENESIS      
  32   5%     3.94E-3   
RNA PROCESSING        33   5%     4.88E-3  
 
Pyrimidine Metabolism        29 1.4%     1.0E-6   
Cell cycle      12   0.6%     1.0E-4  
RNA polymerase      34 1.7%     2.8E-4  
Purine metabolism      15   0.7%     1.2E-3   
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Figure F4.1:  Top 24 candidate tumor suppressor genes. 
 
Genes were ranked according to Pearson correlation coefficient scores (see Chapter 2, Table 1). 
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4.1.2       PCR verification of differentially expressed sterol and TNFR2 signaling pathway 
genes 
Quantitative PCR analysis (Appendix I Section 1.12) was carried out to validate the differential 
expression of genes associated with sterol and TNFR2 signaling pathways. SAA1, SAA2, 
INSIG1 and INSIG2 function as key regulators of cholesterol transport and intracellular 
concentration [87, 88]. TRAF1, A20 (TNFAIP3) and IKB-α are essential downstream 
components of the TNFR2 signaling pathway. By microarray analysis, all seven genes were 
observed to be consistently down-regulated in the segregants in the HvS comparisons. As shown 
in Figures F4.2A and F4.2B, quantitative PCR confirmed the microarray results, showing an 
average of 13-fold repression (9-fold to 18-fold) in the sterol pathway genes, and an average 

































Figure F4.2. Quantitative PCR Analysis. mRNA levels of  
 
A) sterol regulatory genes and  
B) TNFR2 signaling pathway genes we assessed in 11.8 hybrid and 11.8_ts segregant cell lines 
by quantitative real-time PCR. The calculated fold change (See Appendix I 1.12) indicates fold 





































TRAF1 TNFAIP3 IKB-α GAPDH
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4.1.3       Adaptive-quality based clustering of differentially expressed genes 
Genes that share common biological endpoints are often precisely transcriptionally co-
regulated. Thus, to gain further biological insights, we studied the expression patterns of the 
differentially expressed genes by cluster analysis. We applied a method of adaptive quality-based 
clustering to group genes according to the degree of similarity in their microarray expression 
profiles. Compared to other clustering algorithms, adaptive quality-based clustering has the 
advantage of grouping only the most significantly related genes without forcing genes with 
otherwise low correlations into common clusters [89]. Using a stringent probability of cluster 
membership of 0.95, we observed a highly co-expressed cluster of 20 genes down-regulated in 
parental (PvH) and segregant (HvS) cell lines that contained almost all the sterol metabolic genes 
identified in the previous GO and pathway analysis (Tables T4.6 A and T4.6 B). Interestingly, 
this gene cluster also contained the TNFR2 signaling pathway genes: A20 (TNFAIP3), IKB-α 
and TRAF1, indicating, via co-expression, a possible transcriptional link between TNFR2 
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GENE NAME GENE SYMBOL SRE*  P-Value^ 
START DOMAIN CONTAINING 4, STEROL REGULATED STARD4 2 4.10E-04, 1.10E-04 
STEROL-C5-DESATURASE (ERG3 DELTA-5-DESATURASE  
HOMOLOG, FUNGAL)-LIKE SC5DL 1 
2.90E-04 
 
3-HYDROXY-3-METHYLGLUTARYL-COENZYME A REDUCTASE HMGCR 2 2.02E-03, 1.80E-04 
7-DEHYDROCHOLESTEROL REDUCTASE DHCR7 2 9.10E-04, 2.40E-04 
MEVALONATE (DIPHOSPHO) DECARBOXYLASE MVD 1 <1e-05 
TNF RECEPTOR-ASSOCIATED FACTOR 1 TRAF1 1 1.00E-05 
SQUALENE EPOXIDASE SQLE 2 1.10E-04, 3.40E-04 
FATTY ACID DESATURASE 2 FADS2 1 3.90E-04 
FARNESYL-DIPHOSPHATE FARNESYLTRANSFERASE 1 FDFT1 2 3.00E-05, 3.90E-04 
ISOPENTENYL-DIPHOSPHATE DELTA ISOMERASE 1 IDI1 2 6.00E-05, 1.90E-04 
INSULIN INDUCED GENE 1 INSIG1 1 1.0E-05 
TUMOR NECROSIS FACTOR, ALPHA-INDUCED PROTEIN 2 TNFAIP2 1 3.10E-04 
SERINE PALMITOYLTRANSFERASE, LONG CHAIN BASE SUBUNIT 1 SPTLC1 2 <1e-05, 2.00E-05 
STEROL-C4-METHYL OXIDASE-LIKE SC4MOL 1 4.00E-05 
PHOSPHOLIPASE A2 RECEPTOR 1, 180KDA PLA2R1 1 4.50E-04 
HISTONE DEACETYLASE 9 HDAC9 2 1.66E-03, 1.68E-03 
HYDROXYSTEROID (17-BETA) DEHYDROGENASE 7 HSD17B7 2 1.00E-04, 3.30E-04 
ACYL-COA SYNTHETASE SHORT-CHAIN FAMILY MEMBER 2 ACSS2 2 2.31E-03, 7.80E-04 
NUCLEAR FACTOR OF KAPPA LIGHT POLYPEPTIDE GENE 
ENHANCER IN B-CELLS INHIBITOR, ALPHA NFKBIA(IKB-α) 2 4.2E-04, 7.0E-05 
TUMOR NECROSIS FACTOR, ALPHA-INDUCED PROTEIN 3 TNFAIP3 1 1.0E-05 
 
*the number of Sterol Regulatory Element (SRE) motifs identified in promoter regions. 
^P-value indicates the number of times a randomly generated pattern of the same length (as that of SRE) scores a 
PWM score better than the SRE motif. 
 
 
Enriched GO Terms No of Genes % of genes in the 
cluster 
Fisher’s Exact  
P-Value 
sterol biosynthesis 8 5.3 9.1E-10 
steroid biosynthesis 10 6.6 6.1E-9 
lipid biosynthesis 14 9.2 1.5E-8 
cellular lipid metabolism 17 11.2 9.8E-7 
sterol metabolism 8 5.3 1.4E-6 
steroid metabolism 10 6.6 3.4E-6 
lipid metabolism 18 11.8 4.9E-6 
cholesterol biosynthesis 5 3.3 2.0E-5 
 
 
Table T4.6: AQBC analysis results.  
 
A) Members of a 20-gene cluster obtained through the Adaptive-quality based clustering 
(AQBC) algorithm. 
B) Gene ontology enrichment analysis of the 20-gene cluster generated by AQBC. 
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4.1.4       In silico promoter analysis of co-regulated genes 
That the expression patterns of genes comprising the AQBC cluster were highly correlated 
suggests the possibility of transcriptional co-regulation by a common transcription factor. 
Interestingly, several of the sterol metabolism genes identified in this cluster are known to be 
transcriptionally regulated by the Sterol Regulatory Element Binding Proteins (SREBP) [90]. 
SREBPs are basic helix-loop-helix leucine zipper transcription factors that bind to sterol 
regulatory elements (SREs) with DNA sequence ―TCACNCCAC‖ located in the promoter 
regions of sterol metabolism genes[91-93].  
 
Using a web-based DNA sequence motif location and discovery tool we developed at the 
Genome Institute of Singapore (termed BEARR1.0, and which is the subject of the next chapter), 
we analyzed the promoters of the genes within the AQBC 20-gene cluster for putative SREs. The 
transcription factor matrix for SREBP as defined in the TRANSFAC transcription factor database 
(http://www.genome.jp/dbget-bin/show_tfmatrix) was used as input for the BEARR 1.0 promoter 
analysis (Appendix I Section 1.16). Intriguingly, all 20 genes were found to possess at least one 
putative SRE (with 11 genes possessing two SREs), including the three TNFR2 pathway-related 
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4.1.5      Western blot and protein localization studies of the NPC cell lines 
While SREBPs are known to regulate the expression of sterol metabolism genes, they 
have not been implicated in the regulation of genes of the TNFR2 pathway, prompting us to 
further explore this possibility. The SREBPs are comprised predominantly of two genes, 
SREBP1 and SREBP2, with similar biological functions. While our microarray did not contain 
probes for assessing SREBP1 expression, the SREBP2 probes indicated no detectable expression 
of SREBP2 mRNA. Thus, we focused our investigation on the potential involvement of 
SREBP1. First, we asked whether the SREBP1 protein was differentially expressed or showed 
different subcellular localization patterns between nontumorigenic hybrids and tumorigenic 
segregants. Physiologically, the SREBP1 protein exists in one of two biological states: a 
transcriptionally inactive, unmodified 128 kDa protein localized to the nuclear envelope and 
endoplasmic reticulum, or a transcriptionally active form as a cleaved 68 kDa polypeptide 
localized to the nucleus [94].  
 
Western blot analysis of SREBP1 revealed markedly higher levels of the 68 kDa (active) 
peptide in hybrids (compared to segregants) and substantially higher levels of the 128 kDa 
protein (inactive) in segregants relative to hybrids (Figure F4.3A) (Appendix I 1.17). By 
immunofluorescent staining, we observed that SREBP1 is predominantly restricted to the nuclear 
envelope/ER in a segregant line (Figure F4.4A) and localizes to the nucleus in the corresponding 
hybrid line (Figure F4.4B). Together, these observations strongly suggest that SREBP1 is 
transcriptionally active in hybrids and transcriptionally inactive in segregants. 
 
 
  70 
To assess the dependency of TRAF1, TNFAIP3 and IKB-α expression levels on SREBP1 
activity, we conducted siRNA-mediated SREBP1 silencing assays on the hybrid cell lines. 
Knock down of SREBP1 in 11.8 hybrid cells resulted in a substantial decrease in the expression 
of the 68 kDa active form (Figure F4.3B), loss of nuclear staining (Figure 4.4C), and greater than 
a 25-fold reduction in the expression levels of TRAF1, TNFAIP3 and IKB-α (Figure F4.5) 
compared to the same hybrid cells transfected with a scramble siRNA (control). These results 
suggest that the expression levels of all three TNFR2 pathway-related genes are directly 


































Figure F4.3: Western blot of SREBP1.  
 
A) Protein levels of the inactive (128 kDa) and (68kDa) SREBP1 polypeptides in hybrid (11.8, 
11.19) and corresponding segregant (11.8_ts, 11.19_ts) cell lines. 
B) Levels of the active form of SREBP1 are shown in the 11.8 hybrid (siRNA scramble 
















Figure F4.4: Immunofluorescent staining of SREBP1. Shown is SREBP1 staining in  
 
A) 11.8_ts segregant and  
B) 11.8 hybrid cell lines.  
C) Shown is absence of SREBP1 staining in 11.8 hybrid cells silenced for SREBP1 expression 
























Figure F4.5: Quantitative expression analysis of TNFR2 signaling pathway genes.  
 
11.8 hybrid cells transfected with a scramble (control) siRNA or depleted of SREBP1 by siRNA-
mediated knock down were assessed for TRAF1, TNFAIP3 and IKB-α expression by 
quantitative real-time PCR. The calculated fold change indicates fold repression associated with 
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4.1.6 Testing for binding of SREBP1 to gene promoters 
 
To test for a physical interaction between SREBP1 and the promoters of TNFR2 pathway 
genes bearing putative SREs, ChIP assays were carried out on the 11.8 and 11.19 hybrids (see 
Appendix I 1.22). Briefly, immunoprecipitates from SREBP1 and mock pull downs were 
compared for genomic DNA (promoter) detection by RT-PCR using primers specific for 
DHCR7, TNFAIP3, TRAF-1 and IKB-α. DHCR7 is a known SREBP-regulated gene and was 
used as a positive control. Because the IKB-α promoter harbors two putative SRE binding sites, 
RT-PCR was carried out on each SRE separately. In both hybrid lines, we observed a positive 
enrichment for the promoter regions of all the genes in the SREBP1 pull down, suggesting that 
SREBP1 binds to the promoters of each of the genes tested (Figure F4.6A & B). The extent of 



































Figure F4.6: Detecting protein-DNA interactions by SREBP1 CHIP and RT PCR.  
 
Immunoprecipitates from SREBP1 and mock pull downs in  
A) 11.8 and 
B) 11.19 hybrids were compared by RT PCR for the expression of select genes. Positive fold 
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4.1.7       SRE-dependent transcription of TNFR2 pathway genes 
For further evidence that SREBP1 transcriptional activity is responsible for the observed 
expression of TNFR2 pathway genes, we carried out luciferase assays using the regulatory 
regions of TRAF1, TNFAIP3 and IKB-α containing the observed wild type SRE motif or a 
mutant SRE altered by site-directed mutagenesis (See Appendix I 1.20). In a comparison of 
11.19 (hybrid) and 11.19_ts (segregant) cells, the wild type promoters of TNFAIP3 and TRAF1 
were significantly transcriptionally repressed in the segregant cells (Figure F4.7A), while 
repression of the TNFAIP3 and IKB-α wild type promoters was observed in the 11.8_ts 
segregant (compared to the 11.8 hybrid) (Figure F4.7B). While somewhat variable, these results 
were mostly consistent with the differential expression observed of the endogenous genes. Next, 
we compared the luciferase activity of constructs bearing wild type and mutated SREs in the 
hybrid lines. Expression off the TNFAIP3 promoter was highly sensitive to SRE mutational 
status, and showed a highly significant reduction in activity from the mutant SRE in both 11.19 
and 11.8 hybrids (Figure F4.7C & D). The TRAF1 and IKB-α promoters also showed a 
reduction in activity in the presence of the mutant SRE in the 11.8 hybrid, although to a lesser 
extent than TNFAIP3 (Figure F4.7D). Notably, promoter analysis of IKB-α identified two 
putative SRE sites, and a double-site disruption was required to effect a prominent transcriptional 
repression in the hybrids (Figure F4.7C & D inset). Together, these results suggest that 
TNFAIP3 and IKB-α promoters (and perhaps to a lesser extent TRAF1) are dependent on the 



















Figure F4.7: Transcriptional activation from SRE wild type and mutant promoters.  
 
Luciferase assays were conducted using promoter regions of TRAF1, TNFAIP3 and IKB-α with 
or without mutant SREs.  
A) Comparison of luciferase activity between hybrid and segregant (11.19) cells transfected with 
wild type SRE constructs.  
B) Comparison of luciferase activity between hybrid and segregant (11.8) cells transfected with 
wild type SRE constructs. 
C) Comparison of luciferase activity between hybrid cells (11.19) transfected with wild type or 
mutant SRE constructs. 
D) Comparison of luciferase activity between hybrid cells (11.8) transfected with wild type or 
mutant SRE constructs.  The inset in C & D shows the result of transfecting with a IKB-α 
double-mutant construct harboring mutations in each of its two putative SREs. P-values shown in 
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4.2 Discussion 
In our MMCT mouse xenograft model of nasopharyngeal carcinoma, tumorigenic 
HONE1 cells revert to a nontumorigenic ―hybrid‖ phenotype upon introduction of an exogenous 
chromosome 11, and subsequently, convert back to a tumorigenic ―segregant‖ phenotype upon 
loss of critical regions of chromosome 11 and, as we have recently shown, the gain of other 
cytogenetic alterations. Concomitant with these genomic changes, we have observed hundreds of 
reproducible transcriptional alterations that by GO analysis are indicative, significantly, of 
changes in discrete biological pathways including the sterol metabolism and TNFR2 signaling 
pathways.  
 
AQBC cluster analysis of the differentially expressed genes revealed a high correlation 
between the expression patterns of the sterol metabolism and TNFR2 pathway genes, suggesting 
the possible transcriptional co-regulation of these otherwise unrelated signaling compartments. 
Sequence analysis of the gene promoters, provided further support of this hypothesis, as it 
revealed the existence of one or more sterol regulatory elements (SREs), the binding motif 
recognized by the sterol-regulating SREBP transcription factors, in all (20/20) of the clustered 
genes. Thus, we explored the possibility that an SREBP transcription factor might not only 
modulate the expression of sterol metabolism genes [90], but also TNFR2 pathway genes, 
namely, TRAF1, TNFAIP3 and IKB-α, in a manner associated with NPC tumorigenicity. 
 
First, we observed evidence by Western blot analysis and immunofluorescent staining 
that SREBP1 is transcriptionally active in hybrids and transcriptionally inactive in segregants. In 
hybrids, SREBP1 existed predominantly in the 68 kDa active form localized to the nucleus, 
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while in segregants; SREBP1 was observed localized to cytoplasmic perinuclear structures in the 
inactive 128 kDa form. Next, we observed that siRNA-mediated knock down of SREBP1 in 
hybrid cells resulted in a dramatic loss of TRAF1, TNFAIP3 and IKB-α expression. We then 
observed evidence by ChIP-RT PCR that SREBP1 can physically interact with and ―pull down‖ 
the promoter regions of all three genes. Finally, we created luciferase constructs using the SRE-
containing promoter regions of these genes, and demonstrated their transcriptional sensitivity to 
the wild type SRE sequence. In most cases, transcription was repressed in the presence of a 
mutant SRE. Together, these data are consistent with the hypothesis that TRAF1, TNFAIP3 and 
IKB-α, key signaling molecules in the TNFR2 pathway, are transcriptionally activated by 
SREBP1 in nontumorigenic hybrids, and transcriptionally repressed through loss of SREBP1 
activation in tumorigenic segregants. 
 
TNFR2 is the receptor for Tumor Necrosis Factor TNF (a.k.a. Lymphotoxin), a cytokine 
normally produced by activated lymphocytes. TNF mediates a large variety of inflammatory, 
immunostimulatory, and antiviral responses, and is cytotoxic to many tumor cell types. TNF 
receptor (TNFR) associated factors, such as TRAF1, associate with and mediate the signal 
transduction from TNFR2 and other receptors of the TNFR superfamily. In complex with 
TRAF2 and TNFRs, TRAF1 is required for TNF-mediated activation of MAPK8/JNK and NF-
kappa B. NF-kappa B is a transcription factor complex that plays a key role in modulating cell 
survival signals. Downstream of TNF/TRAF signaling, activated NF-kappa B is, paradoxically, 
known to protect cells from apoptosis induced by TNF-alpha, ionizing radiation and 
daunorubricin [95] rather than potentiate cell death. This protective effect is achieved, in part, 
through NF-kappa B-mediated suppression of caspase-8 activation [96, 97]. More recently, NF-
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kappa B has been implicated in the potentiation of angiogenesis. Fujioka and colleagues [98] 
observed that NF-kappa B is constitutively activated in pancreatic adenocarcinoma, and that 
inhibition of NF-kappa B by IKB-α suppressed metastatic progression of AsPc-1 cells 
(pancreatic cancer) in nude mouse xenografts and decreased neoplastic angiogenesis in tumors 
via reduced expression of Vascular Endothelial Growth Factor (VEGF). NF-kappa B-mediated 
induction of angiogenesis through VEGF expression has since been observed in several cancer 
types [99, 100]. Together, these data indicate that activated NF-kappa B can promote tumor 
growth and progression through promoting both anti-apoptotic and pro-angiogenic signals. 
 
Of the TNFR2 pathway genes we discovered to be transcriptionally activated by SREBP1 
in the nontumorigenic hybrids, increased expression of TRAF1, a known activator of NF-kappa 
B, would appear to be more a promoter of cancer progression rather than tumor suppression. 
However, both TNFAIP3 and IKB-α, also transcriptionally activated by SREBP1 in the 
nontumorigenic hybrids, have well defined roles as potent suppressors of NF-kappa B activity 
[101, 102]. TNFAIP3 is thought to inhibit NF-kappa B through ubiquitin-mediated proteolysis 
[103], while IKB-α binds directly to NF-kappa B silencing its transcriptional activity through 
cytoplasmic sequestering [104]. Importantly, both proteins have been shown to suppress 
tumorigenic properties of cancer cells. Zhang et al [105] demonstrated that TNFAIP3 expression 
inhibits invasion of a salivary carcinoma cell line through inactivation of NF-kappa B, while 
antisense RNA suppression of IKB-α was shown to induce malignant transformation of NIH3T3 
cells [106]. 
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Our data, though preliminary, suggest a model of tumor suppression whereby the 
transcriptional activity of SREBP1, the primary regulator of sterol biosynthesis, suppresses 
activation of NF-kappa B through induction of TNFAIP3 and IKB-α. The question thus arises, 
how then might loss of SREBP1 activity occur in NPC, leading to the tumorigenic phenotypes of 
the parental and segregant cells? 
 
Cholesterol is a ubiquitous lipid sterol that plays a key role in the composition of cell 
membranes and the synthesis of steroid hormones. As excess cholesterol can have cytotoxic 
effects, the precise monitoring of its intracellular levels is of high physiological importance 
(Figure F4.8). When cholesterol reaches high intracellular levels, SREBPs are rapidly converted 
to the inactive form, shutting down the expression of cholesterol metabolism genes. 
Concomitantly, excess cholesterol is actively transported out of cells by the serum amyloid 
proteins SAA1 and SAA2. At low cholesterol levels, SREBPs are then shifted to the active form, 
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Figure F4.8: Diagram showing the cholesterol biosynthesis pathway.  
 
Genes that were down regulated in the cancer phenotype parental and segregant cell lines are 
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Interestingly, the key regulators of cholesterol levels, SAA1 and SAA2, are located 
together at the 11p15.1 locus (Figure F4.1) which is absent in the parental cells but present in the 
hybrids (by virtue of MMCT). By density plot analysis, we observed evidence of a prominent 
loss of this same region in the tumorigenic segregant lines (Chapter 3). Taken together, these 
observations are consistent with the hypothesis that loss of SAA1 and SAA2, due to 11p15.1 
deletion in the parental and segregant cell lines, gives rise to high intracellular cholesterol levels 
that repress SREBP1 transcriptional activity. This, in turn, prevents SREBP1-mediated 
expression of TNFAIP3 and IKB-α leading to the activation (via de-repression) of NF-kappa B 
in the parental and segregant lines contributing to their tumorigenicity. 
 
To test this hypothesis, future research will focus on the transcriptional activity of NF-
kappa B in our model, the tumor suppressive roles of SAA1 and SAA2 (can they rescue the 
nontumorigenic phenotype in parental and segregant cells?), and the impact of cholesterol 
reducing agents such as bile acid sequesterants, fibric acid derivatives and HMG-CoA inhibitors 
(i.e., ―statins‖) in reverting the tumorigenic phenotypes through inactivation of NF-kappa B. 
Interestingly, statins are routine cholesterol-reducing drugs that have various pro-apoptotic and 
anti-metastatic activities that could play a role in cancer risk or progression. Prostate cancer 
growth has recently been linked with high cholesterol levels, and statins have been shown to 
have a curative effect on some prostate cancers [107, 108] as well as to significantly reduce the 
risk of advanced prostate cancer [109].  The intersect between SREBP1 activity and de-
repression of NF-kappa B as potential downstream effectors of cholesterol-associated 
tumorigenicity warrants further investigation. 
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Chapter 5: Tools for Exploring the Vocabulary of Transcription Factors 
 
5.0 Transcriptional Response Elements and Gene Regulation 
Gene transcription is a prerequisite of all biological processes, with the essential function 
of producing RNA molecules, such as messenger RNAs that can be translated into the protein 
machinery of a cell. Regulation of transcription is controlled by transcription factors that 
recognize transcriptional response elements or ―binding motifs‖ encoded in the nucleic acid 
sequence of gene promoters. Transcription factors are master regulators of transcriptional 
networks that dictate which biological processes are operational, or not, within a cell. Disruption 
of transcriptional networks is frequently observed in diseases such as cancer, and the study of 
these networks and how they are perturbed in different systems can help to unravel important 
components of biological and pathological processes.  
 
Various genomic strategies such as expression microarrays, for example, enable the 
genome-wide comprehensive monitoring of transcriptional changes within cells. However, how 
these changes relate to distinct (if overlapping) transcriptional networks is not always intuitive. 
The mapping of specific transcription factor binding sites in the cis-regulatory regions of 
differentially expressed genes may allow the identification of direct targets of transcription 
factors, facilitate the parsing of genes into functional transcriptional networks, and identify 
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5.1 Batch Extraction and Analysis of cis-Regulatory Regions (BEARR) 
Some web-accessible computational tools for extracting genomic sequence data and 
analyzing transcription factor binding sites are currently available to researchers, although with 
varying degrees of accessibility, capability and focus. The most comprehensive tools, including 
TOUCAN [110], EZRetrieve [111], the Genomatix suite (www.genomtix.de) and 
TRANSPLORER (www.biobase.de) from BIOBASE (the former two are from academic sources 
and the latter two are only available commercially for batch analysis), usually employ 
annotation-based sequence retrieval and position weight matrices, typically from the 
TRANSFAC database[112] or specialized databases, for sequence extraction (e.g. the upstream 
region extraction tool developed by the Harvard-Lipper Center, 
http://arep.med.harvard.edu/labgc/adnan/hsmmupstream) and binding site identification, 
respectively. There are also stand-alone [e.g. MEME [113], BioProspector [114], MDScan and 
REDUCE] and integrated [e.g. MotifSampler and phylogenetic footprinting modules in 
TOUCAN] motif discovery tools designed to uncover conserved sequences in extracted 
regulatory regions [115, 116]. While the sophisticated approaches in these programs represent 
innovations in comprehensive binding site prediction and discovery and are useful for detailed 
analysis and mining of refined or idealized datasets—for example members of the same gene 
family or known targets of specific transcription factors—nevertheless, based on our experience, 
they may be of limited use against the large amount of ‗noisy‘ data generated in microarray 
studies that often confound the interpretation of the analytical results or fail to yield conserved 
regulatory sequences. Whereas these tools favor comprehensive approaches for identifying all 
known binding sites or conserved sequence discovery in the dataset, we propose that a critical 
and complementary step prior to a more comprehensive analysis and experimental validation is a 
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hypothesis-driven and focused computational strategy based on the experimental design. 
Furthermore, although batch options are available for some of the tools noted, they have not been 
optimized for batch operations and are not suitable for the large amount of data that can be 
generated from genome-scale studies. Therefore, we created Batch Extraction and Analysis of 
cis-Regulatory Regions, or BEARR, to assist biologists in performing batch extraction and 
analysis of cis-Regulatory regions of hundreds or even thousands of differentially expressed 
genes identified in microarray studies. Here, we describe the system design and functionalities.  
 
5.2 System design 
The system is divided into two parts: (i) the regulatory region sequence extraction 
module and (ii) the sequence analysis module. Essentially, the sequence extraction module 
generates the nucleotide sequences, using annotation and genomic sequence databases, to be 
queried by the analysis module, based on transcription factor binding sites or any conserved 
regions defined by the user. The modular system design allows for maximum component 
reusability and extensibility. To ensure platform independence and ease of installation, no 
specialized library or programs were employed (Figure F5.1A & F5.1B). An interactive web-






































Figure F5.1:  BEARR 1.0 workflow. 
 
A) Cartoon representation of the genes upstream and downstream regulatory regions that can be 
extracted using BEARR 1.0 tool. 






























  88 
 
 





  89 
5.3 Regulatory region extraction 
RefSeq accession numbers, recognizable by the NM_ and XM_prefixes, are the primary 
gene identifiers employed in the modules, although the system is capable of translating other 
identifiers from microarray analysis tools, including the UniGene cluster ID and the IMAGE 
clone ID. The list of gene identifiers can be easily copied from the output files of most 
expression analysis tools and pasted into the input window of the extraction module. This input 
feature allows users the flexibility of utilizing the optimal microarray data analysis tools to 
identify differentially expressed genes and then efficiently moving into the extraction and 
analysis of their respective regulatory regions. Currently, BEARR accepts identifiers for human 
and mouse genes.  
 
The sequence extraction module utilizes NCBI's LocusLink and RefSeq [117] databases 
to identify the genes and pinpoint their loci within the genome. These annotations were chosen 
for their comprehensiveness, in terms of number of annotated genes, and their consistency with 
the current state of the NCBI contig databases, the underlying genomic sequence database used 
in BEARR. Using the transcription start site (TSS), defined as the 5'-most nucleotide in the 
reference transcript, and the 3' terminus of the transcript as reference points, the module can 
extract user-defined regions both upstream and downstream of the references. Extraction speed 
has been enhanced by utilizing downloaded databases on the BEARR server rather than 
accessing the information on the NCBI servers via the internet. The resulting sequences are 
saved in the FASTA format and are downloadable by users. It is important to note that the TSS 
locations annotated in LocusLink and RefSeq may only approximate true start sites due to 
incomplete information at the 5' ends of some reference sequences. The large number of 
  90 
annotated genes in LocusLink and RefSeq, however, provides the advantage of maximizing the 
number of regulatory regions we are able to extract for further analysis. To better annotate 
human start sites, we have incorporated the information from DBTSS [118], a database of 
experimentally extended 5' sequences in human transcripts, to assist users in orienting the 
locations of predicted sites with reference to the more accurate TSS. It is also expected that as 
the sequence and annotation information is updated regularly in LocusLink and RefSeq, the 
accuracy of the current extraction method will improve.  
 
 5.4 Sequence analysis 
Once the desired sequences are obtained by the extraction module, the sequence analysis 
subsystem queries the input for putative transcription factor binding sites. Although it may be 
possible to map all known binding sites by incorporating information from TFD [119], 
TRANSFAC [112] and TRRD [120], BEARR is specifically designed to efficiently detect a 
focused group, as determined by experimental design or the microarray data, of transcription 
factor binding sites. We have, however, provided links to the information in TFD and 
TRANSFAC to enable users to extract consensus sites or matrices of their choice for use in 
BEARR. Users also have the option of inputting their own binding sites derived from the latest 
experimental data rather than relying on the potentially dated information in the databases. 
Extracted sequences can be queried using single or multiple consensus binding sites, including 
tandem sites, or position weight matrices of binding sites [PWMs; [121]. Stringency is adjusted 
by defining the number of mismatches or spacer sequences allowed in the consensus searches or 
the similarity score threshold in the PWM output. The PWM score signifies the goodness of the 
match, where higher scores correspond to better matches. An optional empirical P-value 
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calculation is also available for users who wish to assess the statistical significance of the motifs 
being identified against the null hypothesis of finding the motifs in randomly generated 
sequences. The analysis results are displayed in a tab-delimited text file and include the detected 
putative binding sites, number of hits and their positions relative to either 5' end or 3' terminus. 
Additional columns of PWM score, empirical P-value, and DBTSS 5'-extension are also 
included under the appropriate settings (Figure F5.3)). Further information of the analysis 


























Figure F5.3: Sample output from BEARR 1.0.  
 
Sample output from BEARR when used to identify potential functional Estrogen Response 
Element, based on TRANSFAC ERE position weight matrix. Output of consensus pattern 
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In some cases, the user may find it necessary to redefine the published consensus 
sequences or matrices for binding sites because the reported derivations may be based on 
outdated or incomplete information. It is also highly recommended that the users optimize the 
stringency thresholds, using a test set of known target genes of the transcription factors of 
interest, prior to the analysis of the extracted sequences. These parameters will directly impact 
the sensitivity and the specificity of the analysis. For further detailed and comprehensive analysis 
of the extracted sequences, users can upload the FASTA sequence files into other available 
regulatory region analysis tools [e.g. MEME] described above from the links on the website.  
 
5.5  Discussion 
BEARR was originally created to assist the discovery of potential estrogen receptor 
binding sites in the regulatory regions of hormone-responsive genes identified in our microarray 
experiments. We have subsequently used BEARR to analyze expression data from studies of 
other nuclear receptors and transcription factor families in order to identify target genes and 
downstream pathways. In general, this software is well suited for the analysis of data generated 
from study designs where transcription factor activity is manipulated experimentally. The 
software has also been applied in the analysis of the role of transcription factors identified in 
microarray studies of clinical samples in mediating the observed alterations in gene expression 
profiles of diseased tissues. In addition to the analysis of regulatory regions of genes identified in 
array studies, genome-wide surveys (all genes annotated in LocusLink and RefSeq) of 
transcription factor binding sites of interest, within defined regulatory regions, have been carried 
out to determine the frequency and distribution of putative binding sites. In a typical analysis 
flow, a user starts by formulating the underlying hypothesis, followed by designing and carrying 
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out the appropriate experiments while at the same time studying the literature for related 
transcription factor binding sites to construct an initial binding site model. The experiments 
enable the user to group interesting genes, from which BEARR tries to identify potential 
functional binding sites based on the input transcription factor binding site model. Refinement of 
the model might also be necessary. Further biological investigations and experimentations could 
be performed on the binding sites found. Examples, tutorials and analysis workflows can be 
found in the BEARR web page. As more genomes are sequenced and annotated in LocusLink 
and RefSeq, additional databases will be integrated into BEARR to enable users to extract and 
analyze regulatory regions of genes from other model organisms. These upgrades will enhance 
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Chapter 6: Concluding Remarks 
 
Cancer, in its various forms, is the leading cause of death in men and women worldwide; 
yet, the molecular mechanisms of cancer formation and progression remain poorly understood. 
While traditional methods in molecular biology and cytogenetics have led to the discovery of 
some important and therapeutically targetable cancer genes including Her2/neu (for breast 
cancer) and Gleevec (for lymphomas) [122], the discovery process has, in recent years, been 
greatly expedited by the use of cutting edge genomics and proteomics technologies, coupled with 
the recent elucidation of the human genome sequence. For example, through intelligent 
interrogation of microarray expression data, many genes with previously unknown links to 
tumorigenesis have been identified as having important roles in cancer prognosis, diagnosis and 
treatment [123]. 
 
In this work, we have combined experimental and informatics-driven techniques to 
devise a novel approach to the identification of cancer-associated genes. This approach 
combined the power of Microcell Mediated Chromosome Transfer (MMCT) and in vivo models 
of tumorigenesis, with the modern expression microarray and custom bioinformatics tools to 
discover, from a genomic perspective, genes and pathways with putative roles in nasopharyngeal 
carcinoma (NPC). From our analyses, we successfully identified and published the discovery of 
a putative tumor suppressor gene called THY-1 [124]. Through further investigation involving a 
biologically-guided data mining strategy, we discovered evidence of a novel link between 
cholesterol metabolism, SREBP1 activity and NPC, possibly involving the de-repression of NF-
kappa B activation in NPC tumorigenesis.  
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For quite some time a connection between diet and cancer has been known, but the 
molecular details of this association have remained unclear. In the last decade a few studies have 
reported links between cholesterol, lipid levels and cancer, leading to investigations into the 
utility of cholesterol lowering drugs, such as the statins, in cancer treatment and prevention [107, 
108]. Our observation of the possible involvement of SREBP1 inactivation, silencing of 
TNFAIP3 and IKB-, and subsequent de-repression of NF-kappa B in NPC progression may 
shed light on the mechanisms underlying the cholesterol-cancer link, and warrants further 
investigation. 
 
 In conclusion, we posit that the intelligent analysis and integration of genomic read-outs 
of cancer behavior can drive the discovery of meaningful, and sometimes profound, molecular 
mechanisms with therapeutic potential. Beyond intelligent analytical design, perhaps the greatest 
challenge moving forward will be in the area of computational development – finding solutions 
for processing exponentially larger datasets and integrating the numerous platforms now 
available for measuring different aspects of genome dynamics. The post-genomic era is indeed 
perhaps only the beginning of a new age of computational systems-driven science that will have 
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APPENDIX I 
 
1.0  NPC cell lines and culture conditions 
 
The NPC HONE1 cells [125] used as the recipient cell line for monochromosome fusion 
were cultured in Dulbecco‘s Modified Eagle Medium (DMEM) supplemented with 10% calf 
serum (DMEM/10% CS (5% Fetal CS + 5% Newborn CS); Life Technologies, NY, USA). The 
donor mouse hybrid cells MCH 556.15, containing an intact human chromosome 11 tagged with 
a selectable marker, neomycin resistance were grown in DMEM/10% CS containing 600 or 800 
µg/ml of G418 (Geneticin) (Invitrogen, US)   . Micro cell hybrid cell lines 11.8, 11.12, 11.13 and 
11.19 derived by the fusion of HONE1 and MCH556.15 were selected in growth medium 
DMEM/10% CS containing 100 µg/ml streptomycin, 100 U/ml penicillin (Invitrogen, US)   and 
400 µg/ml G418. Tumor segregant cell lines 11.8-3TS, 11.12-2TS, 11.13-1TS, and 11.19-4TS 
which has been derived from their respective Hybrid lines were cultured in DMEM/10% CS 
containing 100 µg/ml streptomycin and100 U/ml penicillin (Invitrogen, US). All the cell lines 
are maintained at 37ºC in a humidified incubator under an atmosphere of 5% CO2 and 95% air. 
 
1.1 Gene expression analysis using oligonucleotide microarray hybridization 
A human oligo-library containing synthesized 60-mers of 18,912 genes was purchased from 
Sigma-Genosys (Woodlands, TX, US). These oligonucleotides were spotted on glass slides using 
GeneMachines Microarray spotter at the Genome Institute of Singapore.  
 
To reduce variations in gene expression caused by culture conditions, we harvested total 
RNA from cells using the RNeasy Midi Kit (Qiagen, Hilden, Germany) at 70-80% confluency 
and 48 h after seeding. We produced cDNA labeled with Cy3 and Cy5 from each sample. 
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Competitive hybridizations were performed in duplicate using Cy3- and Cy5-labeled cDNA 
from each preparation to eliminate background noise caused by possible differences in labeling 
efficiency of the Cy dyes and variable genes. In brief, 20 g of total RNA were reverse 
transcribed into single stranded cDNAs. During this reaction aminoallyl-labelled dUTP (aa-
dUTP) was used along with other deoxynucleotides for the synthesis of cDNAs. The aa-dUTP 
incorporated cDNAs were then coupled with monofunctional Cy3- and Cy5-fluorescent dyes 
(Amersham, Uppsala, Sweden). 
 
The 19K array was pre-hybridized in GeneMachines hybridization chambers in a 42C 
water bath for at least 1 hr. Labeled cDNAs were hybridized to slides in a Maui Hyb 
hybridization chamber (BioMicro Systems, Salt Lake City, UT, US) at 42C for 14 to 16 hr. 
Slides were scanned using GenePix4000S (Axon Instruments, Sunnyvale, CA, USA) and the 
resultant composite images were analyzed by GenePix Pro 4.0 software. The gene expression 
analysis of four pairs of the chromosome 11 microcell hybrids and their tumour segregants 
(HK11.8/HK11.8-3TS, HK11.12/HK11.12-2TS, HK11.13/HK11.13-1TS, and 
HK11.19/HK11.19-4TS) was carried out using GIS Microarray Analysis Database (GIS mAb, 
http://gismadb.gis.a-star.edu.sg).  
1.2 Reverse transcription-polymerase chain reaction (RT-PCR) analysis of THY1 
 
One g of total RNA was reverse-transcribed with 200 U of SuperScript II reverse 
transcriptase (Invitrogen, Carlsbad, CA, US). For PCR amplifications of specific cDNAs of 
THY1 gene, a pair of sense and antisense oligonucleotides was designed with the Primer3 primer 
design program (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi) and the sequences 
were 5'-GACCCGTGAGACAAAGAAGC-3' and 5'-GCCCTCACACTTGACCAGTT-3'. In 
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addition, the primer sequences were chosen from separate exons of the genes so that the RT-
PCR product could readily be distinguished from any genomic DNA-induced PCR product. The 
primer sequences of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were used as 
previously described (6). PCR was performed in a GeneAmp PCR System 9700 programmable 
thermal controller (Applied Biosystems, Foster City, CA, US).  
 
1.3 Identification of the putative THY1 promoter 
The putative THY1 promoter was identified based on the study of Qiu et al.[126]. To 
define the THY1 promoter, the upstream sequence of the THY1 exon 1 was retrieved from UCSC 
Genome Browser (http://genome.ucsc.edu, extracted fragment NT_033899). A moderately GC-
rich putative THY1 promoter was identified by computer analysis (http://www.genomatix.de), 
which is 718 bp, located at 22,837,541-22,838,258 of fragment NT_033899. The 3‘ end region 
spanning this putative promoter fulfilled the criteria of a CpG island, CpG island starts at 402 bp 
and ends at 714 bp; GC content, 70%; observed/expected CpG ratio, 0.602; and a total of 22 
CpG sites in a 313 bp region. 
 
1.4 Methylation-specific PCR (MSP) analysis 
The design of primer pairs for methylated and unmethylated DNA was based on 
MethPrimer (www.urogene.org/methprimer) primer design program using guidelines for MSP 
primer selection (8). The sequences were 5‘-TATTTTTATATTAATGCGGGATCGT-3‘ and 5‘-
CGATTACTACACCCAACTCGAA-3‘ for methylation primers and 5‘-
TTATTTTTATATTAATGTGGGATTGT-3‘ and 5‘-TCCAATTACTACACCCAACTCAAA -
3‘ for unmethylated primers. In brief, 5 g genomic DNA was bisulfite-modified using the 
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CpGenome
TM
 DNA Modification Kit (Chemicon International, Inc, Temecula, CA, US), and 
modified DNA was subjected to PCR. CpGenome
TM
 Universal Methylated DNA (Chemicon 
International, Inc, Temecula, CA, US) was used as a positive control for methylated DNA. For 
each PCR, controls without DNA templates were also included and showed negative results. 
 
1.5 5-Aza-2’-deoxycytidine treatment 
HONE1 cells were seeded in a T75 culture flask 24 h before treatment. Culture medium 
containing 5 M 5-aza-2‘-deoxycytidine (Sigma, St Louis, MO, US) was added to the cells. The 
medium was changed every 24 h. After incubation for 4 d, HONE1 cells were harvested for total 
RNA extraction. 
 
1.6 Western blot analysis of THY1 protein 
Viable NPC cells at 70-80% confluency (5106) were harvested, and then lysed with 
50 mM Tris (pH 7.5), 100 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 
and protein inhibitor mixture (Roche, Nutley, NJ, US). Protein concentrations were measured by 
the Bradford assay (Bio-Rad Laboratories, Munich, Germany). Samples of 20 g cellular protein 
were separated on 10% SDS-polyacrylamide gels and transferred to polyvinylidine difluoride 
(PVDF) membranes (pore size: 0.45 m; Millipore, Billerica, MA, US). The membranes were 
blocked with 5% skim milk and primary antibody incubation was performed with 1:2500 H-110 
(Santa Cruz Biotechnology, Santa Cruz, CA, US) for the THY1 protein, and 1:5000 Ab-1 
(Calbiochem, Darmstadt, Germany) for -tubulin. The signals were visualized by enhanced 
chemiluminescence method according to the manufacturer‘s instructions (Amersham, Uppsala, 
Sweden). 
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1.7 Analysis of Patient specimens 
Eighty NPC specimens and 20 specimens of nasopharyngeal mucosa from non-NPC 
diseases were collected in the Cancer Institute of Sun Yat-Sen University, between 1997 and 
2000.  Ages of the 80 carcinoma patients ranged from
 
14 to 72 years (mean, 47 years old).  The 
male and female ratio is 4.3:1.  The
 
tumour specimens encompassed 50 primary NPC cases 
without metastasis and 30 lymph node metastatic NPC. All NPC cases selected in this study were 
poorly differentiated squamous cell carcinomas. 
 
1.8 NPC tissue microarray (NPC-TMA) 
      The TMA was constructed according to the method described previously[127]. 
 
For the 
construction of NPC TMA, one sample was selected from each case of the 80 NPC‘s (50 primary 
carcinomas and 30 metastatic NPC) and 20 cases of normal nasopharyngeal mucosa. Multiple 
sections (5 µm thick) were cut from the TMA
 
block and mounted on microscope slides.   
 
1.9 Immunohistochemical (IHC) staining 
      Immunohistochemistry studies were performed using the standard streptavidin-biotin-
peroxidase complex method as described[127]. In brief, the TMA slides were incubated with 
rabbit anti-THY1 polyclonal antibody (H-110, Santa Cruz Biotechnology, Santa Cruz, CA, US, 
1:500 dilution)
 
overnight. The slides were then incubated with a biotinylated goat anti-rabbit 
serum for 30 minutes and subsequently reacted with a streptavidin-peroxidase conjugate and 3'-3' 
diaminobenzidine. The nucleus was counterstained using Meyer‘s hematoxylin. For the negative 
control, the primary antibody was replaced with blocking serum.  
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Positive expression of THY1 was primarily a cytoplasmic pattern (Fig. 3).  Both staining 
intensity and positive areas were recorded.  A staining index (values 0 to 9) obtained as the 
intensity of THY1-positive staining (negative = 0, weak = 1,
 
moderate = 2, or strong = 3 scores) 
and the proportion of immunopositive cells of interest (<10% = 1, 10 to 50% = 2, > 50% = 3 
scores), were calculated.  
  
1.10 Gene transfection and colony formation assay 
The full-length wild type THY1 cDNA flanked with BamHI restriction sites [80] was 
ligated to the pCR3.1 neomycin-resistance tagged expression plasmid. The construct containing 
the THY1 gene, pCR3.1-THY1, was confirmed by sequencing on an ABI3100 Sequencer 
(Applied Biosystems, Foster City, CA, US).  PCR3.1-THY1 recombinant and control pCR3.1 
(Invitrogen, Carlsbad, CA, US) vector-alone cell lines were transfected into HONE1 cells with 
Lipofectamine 2000 Reagent (Invitrogen, Carlsbad, CA, US). A total of 4 105 cells were seeded 
in 6-well plates and were transfected with 1 g of plasmid DNA for 5 h. The cells were 
subsequently split into 100 mm dishes. After 14 days of selection in DMEM/10%FCS containing 
400 g/ml neomycin, colonies were fixed and stained with Giemsa to assess the transfection 
efficiency. 
 
Construction of a pETE-Bsd responsive vector and a HONE1 cell line, HONE1-2, 
producing the tetracycline trans-activator tTA as described in Protopopov et al.[68]. The full-
length THY1 cDNA was inserted into BamHI digested pETE-Bsd plasmid containing a selectable 
blasticidin-resistance gene and the recombinant pETE-Bsd-THY1 was verified by sequencing on 
ABI3100 Sequencer (Applied Biosystems, Foster City, CA, US). pETE-Bsd-THY1 and control 
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pETE-Bsd vector were transfected into the HONE1-2 cells as described above. After 14 days of 
selection in DMEM/10%FCS containing 5 g/ml blasticidin and 400 g/ml neomycin with or 
without 0.5 g/ml doxycycline, colonies were fixed and stained.  
 
1.11 Statistical analysis for THY-1 expression 
The X
2
 and Fisher's Exact test were used for analysis of significant differences in THY1 
expression level detected by TMA between primary and metastatic NPC, and in colony numbers 
between control and THY1-transfected cells. Differences were considered statistically significant 
for p values < 0.05. 
 
1.12 Quantitative PCR  
Primer Express software supplied by Applied Biosystems (Darmstadt, Germany) and 
primerbank were used to generate the oligonucleotide sequences [128]. Real-time PCR was 
carried out using the LightCycler® FastStart DNA MasterPLUS SYBR Green I kit (Roche 
Applied Science, Germany) and Light Cycler machine according to the manufacturer‘s protocol. 
The annealing temperature was fixed at 60ºC. Melting curve analysis was carried out to 
determine the specificity of the primers. PFAFFL‘s relative quantification method was used to 
determine the fold changes between the hybrid‘s and segregants [129]. 
 
1.13 FISH 
Metaphase spreads were prepared by following the published procedures. DNA probes 
were labeled with Texas Red (TxR)  and fluorescein isothiocyanate (FITC) (Perkin Elmer) using 
the Bioprime labeling kit (Invitrogen) and hybridized to metaphase spreads from Parental 
(Hone1), Hybrids (11.8 and 11.19) and Segregants (11.8_ts and 11.19_ts) as previously 
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described.
 
The slides were counter stained using 4', 6-diamidino-2-phenylindole
 
dihydrochloride 
in order to visualize the chromosomes. Fluorescent hybridizations signals and DAPI staining 
patterns were captured using an IMAC-CCD=S36 camera attached to a Nikon 80I microscope. 
The images were processed using ISIS (Insitu Imaging System) image processing software 
(metasystems). At least 30 metaphases were examined per probe.  
 
1.14 SKY 
The SKY-Paint DNA kit from Applied Spectral Imaging (Mannheim, Germany) was 
hybridized to metaphase spreads according to the manufacturer's protocol. Chromosomes were 
counterstained with 4′, 6-diamidino-2-phenylindole (DAPI; Sigma, Taufkirch, Germany). The 
multicolor hybridizations were visualized with the Spectra-Cube SD300; spectral analysis and 
classification was done with the SKY-View 1.6 software (Applies Spectral Imaging). A 
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1.15 Modified Fisher’s Exact Score 
DAVID annotation system that was used for the functional annotation analysis adopted a 
modified fisher‘s exact score that was more stringent than the conventional Fisher‘s exact score.  
The difference between the two scores are depicted in the 2x2 contingency table below. 
 
Conventional Fisher‘s exact Score 
 Selected gene list 
Background gene list (All 
the genes in the genome) 
In Pathway A C 
Not In Pathway B D 
 
The modified Fisher‘s exact (Ease Score). 
 Selected gene list 
Background gene list (All 
the genes in the genome) 
In Pathway A-1 C 
Not In Pathway B D 
 
 
1.16 In-silico binding site analysis 
Batch Extraction and Analysis of cis-Regulatory Regions (BEARR) program was used to 
extract and analyze the promoter region of the genes. 3kb base pairs upstream of the transcription 
start site were extracted and analyzed using the PWM module. The PWM for the transcription 
factor was extracted from the transfact database. Log-likelihood approach was adapted in the 
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PWM analysis. The Log-likelihood score measures the ratio of the probability that a subsequence 
is generated by the model (i.e. PWM) versus the probability that the subsequence is generated 
randomly (i.e. using the null background model). The score cutoff 0 (for log-likelihood) carries 
an implicit criterion that sites which are more likely to be generated by the PWM model of 
interest rather than by chance. Further, empirical p-value calculation enables users to easily filter 
the patterns found in a more principled way.  
 
The p-value of each pattern found is based on the null hypothesis that the pattern (with 
the associated PWM score) could be found by chance alone. The p-value is calculated by 
generating 100,000 random sequences of the same length of the pattern and reporting the fraction 
of times the random sequence is scored better or at least as good as the observed one. 
 
1.17 Western blot and immunofluorescence analysis 
The total extracts were harvested from the subconfluent cells as described [130]. Twenty 
micrograms of protein was boiled in 5X sample loading buffer buffer for 5 min and separated 
using sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Proteins were then 
electroblotted onto polyvinyl difluoride membranes (Bio-Rad, ), and nonspecific binding sites 
were blocked for 1 h at room temperature by 5% wt/vol) fat-free milk before an overnight 
incubation at 4°C with specific antibodies: mouse anti-human SREBP-1 (1:1,000), mouse anti-
human SREBP-2 (1:1,000), and mouse anti-human SCAP (1:1000). Anti-human beta-actin 
antibody (1:1000; SantaCruz) was used as a loading control. Primary antibodies were detected 
with horseradish peroxidase-conjugated goat anti-mouse IgG (1:5000; Santa Cruz). Blots were 
then treated with Enhanced Chemiluminescence detection kit (Amersham,) for detecting the 
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protein. Note: for SREBP protein detection, cells were treated with 25 mg/ml ALLN calpain I 
inhibitor; Calbiochem, Merck) for the last 3 h before harvesting, in order to stabilize the short-
lived nuclear forms, as described previously [131].  NPC cells were seeded in Lab-tek 8 well 
chamber slides. Cells were fixed in 4% Para formaldehyde for 15 min at room temperature, 
washed three times, blocked and permeabilized with 5% FBS in 1XPBS/0.3% triton X-100 for 
60 min. Cells were then incubated with primary mouse anti-human SREBP-1 monoclonal 
antibody (1:250) or mouse anti-human SREBP-2 monoclonal antibody (1:250),  in PBS/triton x -
100 at 4C overnight.  After washing, cells were incubated with FITC-conjugated anti-mouse 
antibody (1:750) in PBS/triton for 1-2 hours and washed three times with PBS. 
Immunofluorescence was analyzed using a fluorescence microscope (Nikon,).  
 
1.18 Construction of vectors for luciferase assay 
All the constructs for the luciferase assay were made using the pGL3-Basic vector from 
Promega. The regulatory regions of the genes were determined using the BEARR 1.0 tool. 
Primers were designed to extract 3000bp upstream and 500bp downstream of TSS. The primers 
were designed with the KpnI and SacI restriction enzyme sites to be sub-cloned into the KpnI 
and SacI sites in the vector (Fig 1). 
 
1.19 Disruption of SRE binding sites in the regulatory region 
PWM module of the BEARR 1.0 tool was used to determine the SRE binding sites in the 
genes of interest. The PWM matrix for the SRE binding sites were derived form the transfac 
database for the transcription factor binding sites. Overlap PCR based approach was used for the 
disruption of the SRE binding sites in the regulatory region of the genes. Two internal primers 
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running opposite to each other were designed for the immediate flanking region of the SRE 
binding sites. These primers were tagged with a random sequence that will replace the SRE 
binding sites in the promoter region. The tagging random sequences in the two primers are 
designed in such a way that they are complimentary to each other. Separate PCR reactions were 
carried out to amplify the two separate parts of the regulatory region. The products from these 
PCR reactions were pooled together and PCR amplified using two external primers that were 
designed with the KpnI and SacI sites. Thus the SRE binding sites were disrupted in the 
regulatory regions. These fragments were later sub-cloned in to the pGL3-Basic vector using the 
KpnI and SacI sites (Fig 2). 
 
1.20 Transfection of luciferase constructs in to the NPC cells 
One day prior to the transfection the NPC cells were plated at a concentration of 1-2 x 
10
4
 in 100 µl DEPM/10%FCS medium. The cells were allowed to reach 90-95% confluency. 
The DNA (6 ng of renilla luciferase construct and 150 ng of firefly luciferase construct) and the 
Lipofectamine 2000 were separately diluted using 15 µl of Opti-MEM I reducing medium with 
out serum and Opti-MEMI medium respectively. They were incubated separately at room 
temperature for 5 minutes before combining them together. The mixture was allowed to remain 
at room temperature for 20 minutes after gentle mixing. 30 µl of this mixture were added in to 
the wells containing the cells and the medium and mixed gently by rocking the plate back and 



















Figure A1: Construction of vectors for luciferase assay. 
The Diagram above shows the vector construct using TRAF-1 promoter sequence, Similar 
constructs using TNFAIP3 (A20) and IKB-α were made for luciferase assay. 3000bp upstream of 
the TSS and 500bp downstream of TSS were subcloned with the aid of PCR. Restriction enzyme 
sites KpnI and SacI were introduced in to the primers used for sub cloning the regulatory 
sequences. These sites were later used to subclone them in to the pGL3-Basic vector (Promega). 
Similar constructs were made for all the three genes after disrupting the SRE sites in their 

























Figure A2: Disruption of SRE sites. 
The SRE sites in the TRAF-1, A20 and IKB-α were disrupted with the aid of overlapping PCR. 
Internal primers were selected using the sequences flagging the SRE binding sites. These primers 
were tagged with a random sequence that differs entirely from the SRE binding site signature. 
These random sequences in the two internal primers are designed in such a way that they are 
complimentary. The two PCR reaction products containing the first half and second half are 
pooled and primers spanning the entire full length promoter region was used to amplify the full 











SRE binding site 
Disrupted 
SRE binding site 
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1.21 Luciferase Assay 
The growth media is removed from and the cells were rinsed with 1X PBS. 20 µl 1XPLB 
(Passive Lysis Buffer) was dispensed in to each well containing the cells. The plates were rocked 
for 15 minutes at room temperature. 100 µl LARII (Luciferase assay Reagent) was dispensed in 
to each well and firefly luciferase activity was first measured using Centro
 
LB960 96-well 
luminometer (Berthold Technologies). The firefly luciferase activity was then quenched using 
100 µl of Stop and Glo reagent followed by the measurement of renilla luciferase activity.  
 
1.22 Chromatin immunoprecipitation assays 
 
NPC cells were cultured for 48 h till 80% confluency and treated with 1% formaldehyde 
to cross-link the transcription machinery and the chromatin. Immunoprecipitations were carried 
out overnight with SREBP or GST antibodies (Santa-Cruz Biotechnology) and protein A-
sepharose beads (Zymed). Washing and extraction protocols were adapted from methods 
described previously [62] and PCR reactions were carried out in a LightCycler (Roche 
Diagnostics) real-time system. Thirty six cycles of PCR were carried out on precipitated DNA 
and control DNA using the respective primer sets (Annexe II). PFAFFL‘s relative quantification 
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APPENDIX II 
Quantitative PCR Primers 
1) Insig-1_F  5‘ GCCTACTGTACCCCTGTATCG  
2) Insig-1_R  5‘ TGGTTAATGCCAACAAAAACTGC 
3) SAA1_F  5‘ TCAGGTGAGGAGCACACCAA   
4) SAA1-R  3‘ CCAGGACCAAGGAGCAGAAA  
5) SAA2_F  5‘ TCAGGTGAGGAGCACACCAA   
6) SAA2_R  5‘ CCCGTGAGAAGCTTCATGGT 
7) ABL2_F  5‘ GCAAGAGGCGAATCTGGTG  
8) ABL2_R  5‘ CGTGGTGTAAAGAAGCCTGTG  
9) ALG1_F  5‘ ACAACTGACTCTTGATGGACACA 
10) ALG1_R  5‘ AAGCAGGGGGTAGTCCTCG 
11) MRPL28_F 5‘ CCTGTGCTCCAAGTTTGGGAT 
12) MRPL28_R 5‘ GATCAGCTCCGCCACATAGA 
13) MSLN_F  5‘ ACCCACCTAACATTTCCAGCC 
14) MSLN_R  5‘ AGGAATAGCAGCAGGTCCAAT 
15) NUBP2  5‘ GTGGAGAATATGAGCGGCTTC 
16) NUBP2  5‘ CGTCGCGTCCAGAATCTTC 
17) RHOT2_F  5‘ TGCCTCTTTGTCTCCTCCAAG 
18) RHOT2_R 5‘ CAGGACCCTGTAGAGTGAGAAG 
19) TFAP4_F  5‘ GCAGACAGCCGAGTACATCTT 
20) TFAP4_R  5‘ CCTATGCCTTCGTCCTTGTCC 
21) TMEM8_F 5‘ GCCTCACAAACTACCCAGTCA 
22) TMEM8_R 5‘ CTCGTTCCGCATCTCTGTCTT 
23) ZNF434_F 5‘ GAACCCACGGAGGTAGAAGAT 
24) ZNF434_R 5‘ GCCAATAAACTCCTCTGGACTTT 
25) C1orf9_F  5‘ TGCCGAATCATTGGGAAAATCA 
26) C1orf9_R  5‘ CCACAACTGCATTGGAAGACTC 
27) HSD17B7_F 5‘ AGCCTGAATCTCTCAATCCTCT 
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30) HSD17B7_R 5‘ GCAGTGTCTTCATCTAGGTCCA 
31) MRPS14_F 5‘ GAATACGCAGATGAGAGGCTAC 
32) MRPs14_R 5‘ CGTCATAACACACCGATTTCTGA 
33) RALGPS2_F 5‘ GAGGCCAAGCTGAAAGTTCTAC 
34) RALGPS2_R 5‘ GATAGCCATTTCGTGCCACTC 
 
Luciferase assay construct primers 
35) Traf1_F   5‘ GATCGCGGTACC GAGGTTGGCTGCCCTACAC     
36) Traf1_R   5‘ GGTCACGAGCTC AGCACCAGACCACACAGTGA     
37) TNFAIP3_F 5‘ GATCGCGGTACC CGTGGTGCTCTCTTTCATCA     
38) TNFAIP3_R 5‘ GGTCACGAGCTC AGCGCTTCTGCAAGGTCTAC    
39) IKB-α_F  5‘ GATCGCGGTACC GACAGGGTCTCAGTCTGTTGC     
40) IKB-α_R  5‘ GGTCACGAGCTC ACTTACGAGTCCCCGTCCTC     
41) Traf1_SRE_MF 5‘ CAAGTACAGTACGGCTCTCAGCCCTTCCGGA  
42) Traf1_SRE_MR 5‘ TACTGTACTTGGGCAGGAGGGCTGGTTGGAT  
43) IKBA1_SRE_MF 5‘ CCGGCAGACTACAACAGGTTTTCTCCCCATC  
44) IKBA1_SRE_MR 5‘ TAGTCTGCCGGTCAAAACTGTTTCCCAGAGT  
45) IKBA2_SRE_MF 5‘ AGCAGACGTGGACAATGAAAACTTCCCAGGG  
46) IKBA2_SRE_MR 5‘ CCACGTCTGCTATTATTACCCTGGAGGGTCT  
 
CHIP assay RT-PCR Primers 
47) TRAF1_CF 5‘ GATGGAGGCCCAGTGTAGAA   
48) TRAF1_CR 5‘ CCCCAGTTTCTATCCAACCA 
49) TNFAIP3_CF 5‘ ATTTCCACGGGACTTTCCA 
50) TNFAIP3_CR 5‘ CGAAATGCCCAGGTGACT 
51) NFKBIA1_CF 5‘ GTCTTCTGCCCAGTCTGCTC 
52) NFKBIA1_CR 5‘ CTGCGACTCTGGGAAACAGT 
53) NFKBIA2_CF  5‘ CCAATCCTTCCCCTCTCTTC 
54) NFKBIA2_CR  5‘ TCCCTGGGAAGTTTTCATTG 
55) DHCR7_CF 5‘ GCCGTCAATCTCGAGTCC 
56) DHCR7_CR 5‘ CTAGCCAGGGGTCGGAGT 
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